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ABSTRACT
Efficiently hydrolyzing glucuronide metabolites is an important step in the
analysis of drugs in urine. Amitriptyline and cyclobenzaprine are both tricyclic
compounds with tertiary aliphatic amine groups that are subsequently metabolized to a
less common form of glucuronide metabolite, quaternary ammonium linked glucuronides
(N+- glucuronide). A collaborative study was conducted to investigate discrepancies in
recoveries of these two commonly prescribed compounds in patient urine samples when
hydrolyzed with different enzyme from four different commercially available βglucuronidase sources.
Similarly, there is potential for 6-monoacetylmorphine to be converted to
morphine during β-glucuronidase hydrolysis of urine samples. 6-monoacetylmorphine is
a unique metabolite of heroin and thus a marker of heroin use. A collaborative study was
performed to analyze the degree of 6-monoacetylmorphine (6-MAM) conversion by the
same four commercially available β-glucuronidase enzymes in drug free spiked urine and
patient urine samples.
Meconium is an important biological matrix in determining drug exposure of a
newborn. A novel method for the quantitation of ten commonly prescribed
benzodiazepines and/or their metabolites (7-aminoclonazepam, clonazepam, αhydroxyalprazolam, alprazolam, nordiazepam, diazepam, midazolam, oxazepam,
lorazepam, and temazepam) in meconium was developed using enzymatic hydrolysis,
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WAX-S dispersive pipette extraction (DPX) tips, and LC-MS/MS. The proposed
method minimizes sample volume and sample preparation time. A successful blind study
with a corresponding laboratory verified the effectiveness of the method.
As marijuana continues to be decriminalized, the need for analyses to determine
marijuana impairment for driving under the influence cases rises. An analytical procedure
was developed and validated for the analysis of Δ9-tetrahydrocannabinol (THC) and its
metabolites, 11-hydroxy-Δ9-tetrahydrocannabinol (11-OH-THC) and 11-nor-9-carboxyΔ9-tetrahydrocannabinol (THC-COOH), in whole blood using liquid chromatography
tandem mass spectrometry (LC-MS/MS). An automated DPX method was employed on a
Hamilton NIMBUS96 platform to extract the analytes of interest. A full well plate (96) of
samples could be extracted in less than three minutes. The method was fully validated
according to the Scientific Working Group of Forensic Toxicology (SWGTOX)
guidelines. This method resulted in a successful patient sample comparison with a local
forensic toxicology lab, South Carolina Law Enforcement Division.
The measurement of free catecholamines and metanephrines in the clinical laboratory
is important for the diagnosis of tumors, such as pheochromocytoma. We have developed
an automated, high throughput DPX sample preparation procedure for the selective
extraction of norepinephrine, epinephrine, dopamine, normetanephrine, and metanephrine
in urine. The method was assessed for linearity, sensitivity, precision, accuracy,
carryover, matrix effects and recovery. Using diphenyl borinic acid for complexation and
styrene divinyl benzene for extraction enabled high recoveries and reduced ion
suppression. The simple and high throughput nature of this method would be ideal for
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clinical laboratories experiencing high demand for catecholamine and metanephrine urine
analysis.
Determining the limit of detection (LOD) for a toxicological analytical method is an
important component of method validation. However, with growing applications in an
increasing variety of applications, the recommendation for determining an LOD from
relevant data have evolved in varying directions. Specifically, guidelines often do not
clarify the ambiguities and the effects of different choices associated with the estimate of
uncertainty (standard deviation) for signal-to-noise LOD criteria. Further, LOD is based
on fitting calibration relationship by the method of least squares which require
assumptions (e.g., constant variance) that are rarely addressed. In addition to clarifying
these ambiguities, the application of tolerance intervals for limits of detection
determinations is discussed for forensic dye analysis.

.
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CHAPTER 1
VARIATIONS IN ENZYMATIC HYDROLYSIS EFFICIENCIES FOR AMITRIPTYLINE
AND CYCLOBENZAPRINE IN URINE

Abstract
A collaborative study was conducted to investigate discrepancies in recoveries of two
commonly prescribed compounds, amitriptyline and cyclobenzaprine, in patient urine
samples when hydrolyzed with different enzymes from different sources. A two- to tenfold increase in analyte recoveries was seen for patient samples hydrolyzed using a
recombinant β-glucuronidase (IMCSzymeTM) over samples hydrolyzed with βglucuronidase from Haliotis rufescens. We report outcomes from four commercially
available β-glucuronidase enzymes (IMCSzymeTM, Patella vulgata, Helix pomatia, and
Haliotis rufescens) on patient samples that tested positive for amitriptyline and
cyclobenzaprine. Our results confirm reduced hydrolysis of glucuronides by βglucuronidases isolated from mollusks, but near complete conversion when using the
recombinant enzyme. Our premise is systematic differences in hydrolysis efficiencies due
to varying substrate affinity among enzyme subtypes potentially impacts accuracy and
reliability of measurements.
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Introduction
Amitriptyline and cyclobenzaprine are both tricyclic compounds with tertiary aliphatic
amine groups that are subsequently metabolized to form quaternary ammonium linked
glucuronides (N+- glucuronide). Amitriptyline is a tricyclic antidepressant that was first
introduced in the 1950s (1). Amitriptyline is currently a widely used tricyclic
antidepressant. Cyclobenzaprine is also a tricyclic compound, initially marketed under
the name FlexerilTM in 1977 (2). The drug is a skeletal muscle relaxant commonly
prescribed for acute neck and back pain as well as fibromyalgia treatment (2). Due to its
high potential for abuse, cyclobenzaprine is monitored by many toxicology and pain
management laboratories (3-8).
Cyclobenzaprine and amitriptyline are structurally related and hence metabolize
similarly. Both can be demethylated, oxidized, hydroxylated at the aromatic carbons, and
glucuronidated (9-11). The glucuronides formed are quaternary ammonium-linked
(Figure 1.1). Only trace levels of parent compound are found in urine due to the extensive
metabolism. A pharmacokinetic study showed free unconjugated amitriptyline in urine at
approximately 1% of the initial dose, while amitriptyline glucuronide accounts for 58%
of the urinary metabolites at approximately 25% of the dose taken (9). Similarly,
cyclobenzaprine N+-glucuronide can be present in urine with concentrations up to 50% of
the dose (10). Ideally, glucuronides could be targeted directly for monitoring
amitriptyline or cyclobenzaprine use. Glucuronides typically require extended liquid
chromatography run times, and exhibit poor recoveries with solid phase extractions and
low ionization efficiencies with in electrospray mass spectrometry. Hydrolysis of the
glucuronides should lead to increased concentrations of the parent compounds, providing
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better sensitivity and accuracy for monitoring these drugs. Unfortunately, the quaternary
ammonium linked glucuronides are less common than primary or secondary glucuronides
and have proven to be difficult to hydrolyze with β-glucuronidase enzymes isolated from
mollusks (10, 12-13).
After observing large discrepancies between samples hydrolyzed with Haliotis
rufescens and IMCSzymeTM, a more comprehensive study was conducted to monitor the
hydrolysis of patient samples positive for cyclobenzaprine or amitriptyline with four
different sources of β-glucuronidase enzyme: IMCSzymeTM (genetically engineered E.
Coli), Patella vulgata (limpet), Helix pomatia (Roman snail), and Haliotis rufescens (red
abalone). Patient samples were analyzed before and after hydrolysis with each of the
enzymes and conversion of glucuronide conjugates was monitored by the increase in free
(unconjugated) parent compound. The objective of this study was to evaluate the
hydrolysis of quaternary ammonium-linked glucuronide metabolites with each of the
named target enzymes.
Materials and Methods
Reagents and Standards
Amitriptyline, amitriptyline-d3, and cyclobenzaprine drug standards were purchased from
Cerilliant Corporation (Round Rock, TX). The amitriptyline glucuronide standard had a
listed concentration of 1000 ng/mL and was provided by TLC Pharmaceutical Standards
(Ontario, Canada). Disposable pipette extraction (DPX) tips were provided by DPX
Technologies, LLC (Columbia, SC); the 1 mL RP-S tips contain styrene divinyl benzene
sorbent with salt. IMCSzymeTM was obtained from Integrated MicroChromatography
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Systems, LLC (Columbia, SC). Haliotis rufescens β-glucuronidase was purchased from
Campbell Science (Logan, UT). Helix pomatia and Patella vulgata enzymes were
purchased from Sigma Aldrich (St. Louis, MO). All solvents were LC-MS Optima grade,
from Fisher Scientific (Waltham, MA).
Specimens
Five urine samples positive for amitriptyline and five urine samples positive for
cyclobenzaprine were obtained from PSO laboratory (Lansing, MI); all samples were
anonymously coded. All ten samples were analyzed in the initial method comparison
study using Haliotis rufescens (with results obtained by PSO Lab), and IMCSzymeTM
(analyzed several days later). Further studies of the hydrolysis of spiked samples using
other enzymes were conducted and presented herein. Patient samples, one positive for
amitriptyline and one positive for cyclobenzaprine, were also analyzed using the various
enzymes for direct comparison.
Sample Preparation
The following procedures were used for both the method comparison and the consequent
enzyme hydrolysis comparison. Urine samples were prepared by aliquoting 200 µL into a
2 mL micro centrifuge tube (VWR, Radnor, PA). A master mix solution containing 10
µL of 1000 ng/mL amitriptyline-d3 in methanol, 50 µL of hydrolysis buffer, and 40 µL of
enzyme were added to the urine. Rapid hydrolysis buffer was provided by the vendor for
IMCSzymeTM and 1 M sodium acetate at pH 4.5 was used for the other three enzymes.
IMCSzymeTM had an activity of > 50 kU/mL, while Helix pomatia, Patella vulgata, and
Haliotis rufescens were > 100 kU/mL. Samples were heated and vortexed at 60 C and

4

550 RPM for 30 min. with IMCSzymeTM and 1 h for the other enzymes using a Labnet
VorTempTM 56 Benchtop Incubator/Shaker (Woodbridge, NJ). These hydrolysis time and
temperature were consistent with manufacturer specifications.
Subsequent to hydrolysis, 500 µL acetonitrile was added to each sample, and
disposable pipette extractions were performed by aspirating and dispensing the sample
solutions in and out of the DPX (RP-S) tips. The extraction produces two distinct layers,
aqueous solution containing salts on the bottom and acetonitrile containing analytes of
interest on the top. After transferring a 300 µL portion of the top acetonitrile layer to a
vial, and adding 700 µL water, the samples were ready for analysis.
Calibrators and Controls
All calibrators and controls were prepared in drug-free urine, obtained from healthy
volunteers. The calibration design used for the method comparison study included eight
concentration points at 0, 50, 100, 250, 500, 1000, and 2000 ng/mL of amitriptyline and
cyclobenzaprine. Calibrations were done in duplicate to account for the difference in
buffer pH needed for IMCSzymeTM (pH ~7.4) and Haliotis rufescens, Patella vulgata,
and Helix pomatia (pH ~4.5).
Instrumental Analysis
Analyses were performed using a Thermo TSQ VantageTM triple quadrupole mass
spectrometer (Milwaukee, WI) coupled to an Agilent 1100 Series HPLC (Agilent
Technologies, Waldbronn, Germany) equipped with an Agilent Poroshell EC-C18
column (3.0 x 50 mm, 2.7 µm). Sample injections of 20 µL were made using a 6 port
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(0.25 mm) Cheminert C2V injection valve (Houston, TX) incorporated on a dual rail
GERSTEL MPS autosampler (Linthicum, MD).
The mobile phase was composed of 0.1% formic acid in water (A) and 0.1% formic
acid in acetonitrile (B). The gradient started at 70% A for 0.5 min., ramped to 5% A at 3
min., held at 5% A at 3.5 min, and then changed back to 70% A. The total run time was 6
min. Eluent was diverted to waste during the intervals of 0-0.75 and 4.5-6 min. after the
injection. The column flow rate was 0.4 mL/min. Mass spectrometer parameters were:
electrospray voltage, 4000 V; auxillary gas pressure, 60 psi; sheath gas pressure, 47 psi;
vaporizer temperature, 400 °C; auxillary gas temperature, 24 °C; capillary temperature
350 °C. The selected ion pairs for multiple reaction monitoring (MRM) for each analyte
can be found in Table 1.1.
Results and Discussion
Comparative Study with 10 Patient Samples
Researchers at PSO laboratory recognized a discrepancy between hydrolysis results of
Haliotis rufescens and IMCSzymeTM in a number of patient samples, and donated
samples to the University of South Carolina (USC) for further investigation. Patient
sample results comparing IMCSzymeTM and Haliotis rufescens are summarized in Table
1.2, showing the concentrations of the unhydrolyzed parent compound (amitriptyline/
cyclobenzaprine) and concentrations of the parent compound after hydrolysis
(hydrolyzed). The amount of glucuronide conjugates can be calculated from hydrolyzed
versus unhydrolyzed concentration of the parent compound. The IMCSzymeTM and
Haliotis rufescens unhydrolyzed sample concentration should be the same. Differences,
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however, can potentially be attributed to hydrolysis in the two month storage time
between analyses.
IMCSzymeTM and Haliotis rufescens produced different hydrolyzed parent compound
concentrations, ranging over almost an order of magnitude. For example, in patient
sample 42756, the hydrolyzed concentration of cyclobenzaprine using IMCSzymeTM was
4153.0 ng/mL; the hydrolyzed concentration using Haliotis rufescens was only 450.4
ng/mL. The amount of glucuronide conjugates hydrolyzed by the Haliotis rufescens was
consistently lower in all samples compared to that produced by IMCSzymeTM. Thus,
enzyme choice (Haliotis rufescens for PSO, and IMCSzymeTM for this method)
significantly impacted the amount of glucuronide converted. Consequently, further
experiments were performed evaluate the ability of four commercially available βglucuronidase enzymes to hydrolyze this unique class of glucuronides.
Glucuronides were monitored using the same product ions as the parent compounds
shown in Table 1.1. These measurements enabled qualitative assessment of the
glucuronide decrease as a result of hydrolysis, and to monitor consistency of the
relationship between the parent compound peak area increase and glucuronide peak area
decrease as a result of hydrolysis. The ratio (∆[Parent]/∆[Glucuronide]), shown in Table
1.3, can be employed to ascertain the likelihood that the increase in parent compound is a
direct result of glucuronide decrease. If the ratio remains consistent throughout the
patient samples, then it is likely that the parent compound peak area increase is a direct
result of the glucuronide peak area decrease. However, if the ratios are highly variable,
then it is likely there is a confounding factor causing the parent compound increase.
Ratios for IMCSzymeTM data were consistent (approximately 6 for cyclobenzaprine and
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18 for amitriptyline) except when the glucuronide peak areas for unhydrolyzed
compounds were low (~30,000 area counts). This occurred for patient samples 48675 and
42746, which were most likely outside the linear dynamic range. We therefore concluded
that the observed parent compound peak intensity increases were a direct result of
glucuronide hydrolysis.
Hydrolysis of Amitriptyline Glucuronide Standard in Drug Free Urine
Drug-free urine was spiked with the acquired amitriptyline glucuronide standard.
However, the concentration of amitriptyline glucuronide standard that was provided was
inaccurate for two reasons. After “complete” hydrolysis (where no glucuronide peak was
detected), the yield of amitriptyline did not match the manufacturer’s specified
amitriptyline glucuronide concentration. Further, amitriptyline was also present in the
glucuronide standard solution, thus suggesting degradation had occurred. Therefore,
calibration for product amounts was not conducted, and the peak areas of both
compounds were monitored before and after hydrolysis.
The four sources of β-glucuronidase chosen here include a genetically engineered βglucuronidase and three different types of sea snail sources. The goal of this work was
not to find the optimum hydrolysis conditions for different enzymes, but rather, to
compare their relative hydrolysis efficiencies. For that reason, the manufacturer
recommendations for hydrolysis conditions were followed as described in the
Experimental section.
Average peak areas for amitriptyline and amitriptyline glucuronide before and after
hydrolysis with each of the enzymes are shown in Table 1.4. Percent hydrolysis was
calculated as
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% hydrolysis = (1 – A/B) × 100%

(Equation 1)

where A is the average ratio (n = 3) of amitriptyline glucuronide peak area to internal
standard peak area for post-hydrolysis, and B is the average ratio (n = 3) of amitriptyline
glucuronide peak area to internal standard peak area for pre-hydrolysis.
IMCSzymeTM achieved 99.3% hydrolysis in 30 min. of incubation. The three mollusk
enzymes (Helix pomatia, Haliotis rufescens, and Patella vulgate) produced 6.3%, 23.2%,
and 31.4% hydrolysis, respectively, in 1 h. of incubation. The incubation times employed
are based on manufacturer recommendations and common laboratory procedures for the
respective enzymes. Amitriptyline glucuronide peak area decrease and amitriptyline peak
area increase, when comparing pre-and post-hydrolysis chromatograms for each enzyme,
as shown in Table 1.4.
Hydrolysis of Patient Samples by Four Different Enzymes
Further experiments to estimate the percent glucuronidation in actual patient samples
were performed for the same four enzymes. In this case, however, the percent
glucuronidation was calculated based on monitoring changes in the concentration of the
parent compound (amitriptyline or cyclobenzaprine). The calculated percent
glucuronidation for each enzyme can be compared to average ratios reported in the
literature for parent and glucuronide metabolites in human urine. We assume that if
calculated glucuronidation percentages are similar to reported averages, then the enzyme
likely converted close to all of the available glucuronide.
The patient samples chosen for comparison of hydrolysis capability were patient
sample 49187 (positive for cyclobenzaprine), and 42748 (positive for amitriptyline).

9

Samples (n = 2) were analyzed for amitriptyline or cyclobenzaprine before hydrolysis
(unhydrolyzed), and after hydrolysis (hydrolyzed) for each of the four enzymes. The N+glucuronide metabolites of cyclobenzaprine and amitriptyline were resistant to hydrolysis
with Helix pomatia, Patella vulgata, and Haliotis rufescens, but not with IMCSzymeTM.
Table 1.5 shows total parent compound (amitriptyline/cyclobenzaprine) concentration
(ng/mL) prior to hydrolysis (“unhydrolyzed”), and after hydrolysis (“hydrolyzed”) with
each of the four β-glucuronidase enzymes. Based on these values, the percent
glucuronidation is calculated as the percentage of glucuronide metabolite compared to
amount of total parent compound after hydrolysis, and represents the relative amount of
hydrolyzed glucuronide produced by each enzyme. Hence, the percent glucuronidation
increases with the increase in hydrolysis of the glucuronide metabolites.
Of the four enzymes tested, IMCSzymeTM converted the highest amount of
amitriptyline N+-glucuronide during hydrolysis (95.3%). The other enzymes exhibited
glucuronidation percentages ranging from 57.8-67.5 %. The glucuronidation percentage
with IMCSzymeTM hydrolysis is consistent with reported amitriptyline and amitriptyline
glucuronide concentrations from metabolism studies in the literature. Using a hot alkali
treatment (2 M sodium hydroxide at 100 °C for 15 min.), Dahl-Puustinen, et al. (14)
found free amitriptyline concentration in urine to be 0.45 ± 0.46 % of total dose, while
amitriptyline glucuronide was found to be 8.2 ± 3.2 % of total dose. These values
represent an average of 94.8 % glucuronidation. Other studies report that excreted
amitriptyline N+-glucuronide is 5-10 % of the administered dose, and that free
amitriptyline constitutes 0.2-0.4% of the dose (10). These results imply 92-98 % binding
of glucuronide conjugates. Lastly, Rana, et al. (1) reported an average of 90 %
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glucuronidation for amitriptyline in urine using K12 β-glucuronidase from E. coli at 52
°C for one h.
Our results show that the concentration of cyclobenzaprine post-hydrolysis with
IMCSzymeTM was much higher than the post-hydrolysis cyclobenzaprine concentrations
for the other enzymes. The IMCSzymeTM post-hydrolysis concentration of
cyclobenzaprine was 2322.6 ± 16 ng/mL, while the concentration of free cyclobenzaprine
in the unhydrolyzed sample was 144.4 ± 11 ng/mL, which correlates to a glucuronidation
percentage of 93.8%. The other three enzymes had percentages that ranged from 52.072.9%. The IMCSzymeTM glucuronidation percentage is comparable to the free
cyclobenzaprine and cyclobenzaprine glucuronide ratios found in the literature. Hucker,
et al. (11) reported 1.7 % of metabolites in urine as free cyclobenzaprine and 34.0% was
attributed to the N+-glucuronide during the first 24 h. after administration–an average
glucuronidation percentage of 95.2%. Between 24 and 48 h. 1.1 ± 0.6 % of metabolites in
urine was free cyclobenzaprine, and 24.1 ± 6.9% was cyclobenzaprine glucuronide,
corresponding to an average glucuronidation percentage of 95.6%. Hucker’s study was
carried out over five days. Cyclobenzaprine was present for the first 48 h. while
cyclobenzaprine glucuronide was present for all five days. High hydrolysis efficiency
from IMCSzymeTM for cyclobenzaprine glucuronide increases sensitivity and provides a
longer window of detection for the parent compound.
We employed drug-free urine spiked with amitriptyline glucuronide standard to
provide known reference samples for testing hydrolysis efficiency for the four different
enzymes. Percent hydrolysis ranged from 6.3% with Helix pomatia in one h., to 99.3%
with IMCSzymeTM in 30 min. This amitriptyline glucuronide standard hydrolysis study
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was performed at a relatively low level (~1000 ng/mL) of amitriptyline glucuronide at
which the enzymes perform optimally. However, patient samples often have a much
greater glucuronide concentration. Thus, when comparing the post-hydrolysis
glucuronide amounts in both the patient sample study and the glucuronide standard study,
the three snail sourced enzymes performed more poorly. For example, Patella vulgata
hydrolyzed approximately 30% of the amount that IMCSzymeTM did in the low
glucuronide spiked urine. However, in patient samples, Patella vulgata only hydrolyzed
approximately 13% of that hydrolyzed by IMCSzymeTM (based on post-hydrolysis
amitriptyline concentrations). Use of IMCSzymeTM provided ratios of parent compound
to glucuronide most consistent with the literature reports of average human excretion
patterns (6, 10-11). The other three enzymes convert less amitriptyline and
cyclobenzaprine glucuronide, even under more rigorous conditions (i.e., longer
hydrolysis time and higher activity). This variation of hydrolysis based on enzyme source
for N+-glucuronides is consistent with previous literature. Kowalczyk, et al., compared
the ability of three different enzymes (bovine liver, E. coli, and Helix pomatia) to
hydrolyze two cyclic and two acyclic quaternary ammonium-linked glucuronide
metabolites. This work showed that the enzymes hydrolyzed the compounds to different
degrees and adjustment of buffer pH and amount of enzyme did not achieve complete
hydrolysis (13).
Conclusion
Although variation in hydrolysis of these quaternary ammonium-linked glucuronides
with enzyme source is evident, the high degree of hydrolysis with IMCSzymeTM provides
a reliable β-glucuronidase source for amitriptyline and cyclobenzaprine N+-glucuronide
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hydrolysis. Hydrolysis efficiencies may vary due to many factors, including impurities in
the enzyme solution, and/or differing binding affinities for this specific class of
glucuronides. Large discrepancies in the hydrolysis efficiency of different enzymes is of
great practical significance due to the potential for incomplete hydrolysis of samples.
Insufficient hydrolysis results in limited sensitivity and positive samples may fall below
limits of detection and/or limits of quantitation. Results presented here demonstrate that
enzyme choice and/or optimal hydrolysis conditions should be evaluated specifically for
N+-glucuronides. Other combinations of N+-glucuronide metabolites of different drugs
(30+ known) and sources of β-glucuronidase may produce different hydrolysis results.
For both amitriptyline and cyclobenzaprine, Helix pomatia, Patella vulgata, and
Haliotis rufescens produced lower hydrolysis efficiencies for amitriptyline N+glucuronide and produce glucuronide percentages in patient samples well below literature
reported human metabolism ratios of these drugs. IMCSzymeTM hydrolysis resulted in
calculated glucuronidation percentages closer to the literature averages in half the
hydrolysis time. Based on the data reported, we conclude that IMCSzymeTM is more
efficient at hydrolyzing these N+-glucuronide metabolites (at the conditions tested) and
could improve the sensitivity of the analysis of these compounds.
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Table 1.1
Ions selected for multiple reaction monitoring.
Analyte
Parent
Amitriptyline
Amitriptyline d3
Amitriptyline glucuronide
Cyclobenzaprine
Cyclobenzaprine glucuronide

278
281
454.2
275.9
452.2
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Ions
Products
91.1, 233.0
190.9, 233.0
91.1, 233.0
215.9, 231.0
215.9, 231.1

Table 1.2
Comparison of patient sample cyclobenzaprine and
amitriptyline concentrations (ng/mL) prior to hydrolysis
(unhydrolyzed), and after hydrolysis (hydrolyzed) in after
use of IMCSzymeTM and Haliotis rufescens (red abalone)
(NF = not found).
Cyclobenzaprine
IMCSzymeTM
Patient Sample
Unhydrolyzed
Hydrolyzed
42756
1407
4153
48675
3618
3918
48678
NF
NF
48735
298
2985
49187
167
2715
Haliotis rufescens
Patient Sample
Unhydrolyzed
Hydrolyzed
42756
29
450
48675
214
661
48678
NF
87
48735
81
170
49187
33
182
Amitriptyline
Patient Sample
42746
42748
42753
48663
48665

Patient Sample
42746
42748
42753
48663
48665

IMCSzymeTM
Unhydrolyzed
7
117
47
587
35
Haliotis rufescens
Unhydrolyzed
6
67
26
312
20
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Hydrolyzed
95
2253
799
4175
1542

Hydrolyzed
11
85
76
496
191

Table 1.3
Comparison of peak areas for parent (cyclobenzaprine/amitriptyline) and glucuronide
conjugates before and after hydrolysis with IMCSzyme™ as described in Sample
Preparation (NF = Not Found, N/A = Not Applicable).
Cyclobenzaprine
glucuronide

Cyclobenzaprine

∆[Parent]/
Patient
Unhydrolyzed Hydrolyzed Unhydrolyzed Hydrolyzed
Sample
∆[Glucuronide]
42756
820983
1182
2904217.4
7440808.8
5.5
48675
31197
NF
10290532
11237703
30.4
48678
NF
NF
930.5
2799.9
N/A
48735
1305618
912
665501.5
9123170.9
6.5
49187
735546
929
380286
6597721.7
8.5
Amitriptyline glucuronide

Amitriptyline

∆[Parent]/
Patient
Unhydrolyzed Hydrolyzed Unhydrolyzed Hydrolyzed
Sample
∆[Glucuronide]
42746
31269
NF
5114
308288
9.7
42748
372287
4938
480017
6824697
17.3
42753
162822
1823
199265
3072325
17.9
48663
696569
11806
2158599
15531667
19.5
48665
247575
233
133743
4702824
18.5

18

Table 1.4
Average peak areas (n = 3) before and after hydrolysis with Helix pomatia, Haliotis
rufescens, Patella vulgata, and IMCSzymeTM and subsequent calculated percent
hydrolysis.
Average Peak Area
% Hydrolysis
Am. Gluc.
Amitriptyline Am. Gluc./I.S.
Helix pomatia
Pre-Hydrolysis
126093.1
11987.6
0.293
6.3
Post-Hydrolysis
123873.1
34786.1
0.274
Haliotis rufescens
Pre-Hydrolysis
116697.4
13315.4
0.255
23.2
Post-Hydrolysis
92136.2
96844.6
0.196
Patella vulgata
Pre-Hydrolysis
112592.8
12715
0.244
31.4
Post-Hydrolysis
76658.2
137821.6
0.168
IMCSzymeTM
Pre-Hydrolysis
Post-Hydrolysis

107857.2
500.3

16285.1
356913.9
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0.194
0.001

99.3

Table 1.5
Amitriptyline and cyclobenzaprine concentrations (mean  standard
deviation, ng/mL) (n = 2) post-hydrolysis for each enzyme and the
calculated percent glucuronidation based on concentrations of parent
drug pre-hydrolysis (N/A = not applicable).
Amitriptyline
Total Parent Concentration % Glucuronidation
Unhydrolyzed
88.4 +/- 2.1
N/A
TM
IMCSzyme
1892.6 +/- 21.4
95.3
Helix pomatia
209.3 (one rep)
57.8
Patella vulgata
245.8 +/- 2.8
64.0
Haliotis rufescens
271.9 +/- 3.1
67.5
Cyclobenzaprine
Total Parent Concentration % Glucuronidation
Unhydrolyzed
144.4 +/- 10.9
N/A
TM
IMCSzyme
2322.6 +/- 16.1
93.8
Helix pomatia
300.9 (one rep)
52.0
Patella vulgata
523.7 +/- 3.6
72.4
Haliotis rufescens
532.8 +/- 3.7
72.9

20

Figure 1.1 Structures of amitriptyline, cyclobenzaprine, and their N+-glucuronides.
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CHAPTER 2
ASSESSMENT OF 6-MONOACETYLMORPHINE CONVERSION DURING
HYDROLYSIS WITH DIFFERENT β-GLUCURONIDASES

Abstract
There is potential for 6-monoacetylmorphine, a unique metabolite of heroin, to be
converted to morphine during β-glucuronidase hydrolysis of urine samples. Loss of 6monoacetylmorphine from the sample under analysis is detrimental to the determination
of heroin use. Therefore, laboratories are forced to analyze opiate positive urine samples
before and after hydrolysis to limit false negative heroin results. The increase in samples
to analyze propagates backlog and increases cost.
A collaborative study was performed to determine the degree of 6monoacetylmorphine (6-MAM) conversion by four commercially available βglucuronidase enzymes (IMCSzymeTM, Haliotis rufescens, Helix pomatia, and Patella
vulgata) in drug free spiked urine and patient urine samples. The hydrolysis was
performed at the specified temperature at 0, 1, and 2 h hydrolysis time intervals. 6-MAM
and morphine levels were compared at each time interval to determine the amount of 6MAM loss and corresponding morphine increase. The extent of 6-MAM conversion
varied for each β-glucuronidase from 3 to 47% over 2 h. Choosing a β-glucuronidase that
minimizes 6-MAM conversion would help conserve valuable resources.
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Introduction
Heroin (3,6-diacetylmorphine) was first synthesized in 1874 as an antitussive. Heroin use
drastically increased after the Vietnam War; approximately 42% of returning service
members reported use. Heroin eventually became a Schedule I Substance, but there are
still approximately 980,000 “hard core” users in the United States and 1.2-1.5 million
total users (1). Due to its illicitness and highly adverse side effects, urine drug testing is
routine for workplace, pre-employment, pre-trial, and criminal/death investigations, and
in other situations in which effects of impairment are observed with individuals who are
subsequently suspected of illicit drug use.
Due to the very short half-life of heroin (~2-8 min), detection of abuse using urine
must rely on its metabolites (2, 3-9). Drug testing for heroin first began by monitoring for
morphine, a known metabolite of heroin (Fig. 2.1). However, morphine is also a
metabolite of codeine, and can also be found as a result of poppy seed ingestion, thus
producing an increased likelihood of false positives for heroin presence. In 1994, the
Department of Defense and the Department of Health and Human Services mandated
testing for 6-monoacetylmorphine (6-MAM) because it is a metabolite exclusively for
heroin (1, 10).
Today, analysis of opiates often includes hydrolysis via a β-glucuronidase for
removal of the glucuronide moiety from glucuronidated metabolites for increased
sensitivity. Unfortunately, a significant problem lies with the use of β-glucuronidase
enzymes and their potential to convert 6-MAM to morphine. Initial 6-MAM levels in
urine are often low as a result of a half-life of 10-40 min and a detection window of 2-24
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h after intake (9). If 6-MAM conversion via the β-glucuronidase is significant, then 6MAM may fall below detection limits, and definitive heroin use may be inconclusive. To
avoid inaccurate quantitation of 6-MAM and morphine as a result of conversion during
hydrolysis, laboratories have to analyze both hydrolyzed and unhydrolyzed opiate
positive samples to monitor potential 6-MAM loss and morphine increase. This extra
sample load requires time and money.
It is generally understood that β-glucuronidase enzymes effectively hydrolyze
glucuronide conjugates, which is their primary purpose in opiate positive samples.
However, their ability to convert 6-MAM to morphine undesirably has not been
evaluated. Herein, we compare four commercially available β-glucuronidase enzymes,
Haliotis rufescens, Helix pomatia, Patella vulgata, and IMCSzymeTM, for their ability to
convert 6-MAM to morphine using both controlled samples and patient samples.
Materials and Methods
Reagents and Standards
Morphine, 6-Monoacetylmorphine, and codeine-d6 drug standards were purchased from
Cerilliant Corporation (Round Rock, TX). Disposable pipette extraction (DPX) tips (type
RP-S) were provided by DPX Technologies, LLC (Columbia, SC). IMCSzymeTM was
obtained from Integrated MicroChromatography Systems, LLC (Columbia, SC). Haliotis
rufescens β-glucuronidase was purchased from Campbell Science (Logan, UT). Helix
pomatia and Patella vulgata enzymes were purchased from Sigma Aldrich (St. Louis,
MO). All solvents were LC-MS Optima grade, from Fisher Scientific (Waltham, MA).
Specimens
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Spiked urine was used for direct analysis of 6-MAM conversion to morphine for all of
the enzymes. Three urine samples positive for 6-MAM were obtained from PSO
laboratory (Lansing, MI), all samples were anonymously coded, and used to compliment
and confirm 6-MAM conversion in patient samples.
All calibrators and controls were prepared in drug-free urine. The two calibration curves
consisted of morphine and 6-MAM at 0, 10, 50, 100, 500, and 1000 ng/mL. One
calibration curve was prepared with the buffer solution appropriate for Haliotis rufescens,
Helix pomatia, and Patella vulgata (pH 4.5) with sucrose in place of the enzyme. The
other calibration curve was prepared with IMCSzymeTM and its appropriate buffer at pH
7.4. Quality control samples were also prepared using drug-free urine. Six total quality
controls positive for 6-MAM were used, three at 10 ng/mL and three at 100 ng/mL.
Hydrolysis and Sample Preparation
Hydrolysis of 200 µL urine was performed by adding 100 µL of the hydrolysis solution
containing hydrolysis buffer (0.2 M potassium phosphate buffer at pH 7.4 for
IMCSzymeTM) and 1M sodium acetate buffer at pH 4.5 for the other three enzymes, in
addition to a β-glucuronidase and codeine-d6 internal standard at a ratio of 2:2:1,
respectively. Samples were heated and mixed at 55 C using a Labnet VorTempTM 56
Benchtop Incubator/Shaker (Woodbridge, NJ). Subsequently, 400 µL acetonitrile was
added to each sample, and the solution was extracted using DPX-RP-S tips. This
extraction results in separation of acetonitrile (containing drugs of interest) from water
(containing salts and many interferences), after which 50 µL of the top acetonitrile layer
was transferred to a 96-well plate. The solvent was evaporated and reconstituted with 200
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µL of water/methanol (95/5). Hydrolysis with the 3 other enzymes was performed
similarly, except the hydrolysis was carried out at 55C using NaOAc buffer (167 mM,
pH of 4.5).
For the controlled samples, the 6-MAM and morphine concentrations were
monitored at time 0, after 1 h of incubation, and after 2 h of incubation with each
enzyme. For the patient samples, each sample was hydrolyzed according to the
manufacturer specified hydrolysis time, which was 30 min for IMCSzymeTM and 2 h for
the other three enzymes.
Instrumental Analysis
Analyses were performed using a Thermo TSQ Vantage triple quadrupole system
(Milwaukee, WI) with an Agilent 1100 HPLC (Santa Clara, CA) equipped with an
Agilent Poroshell EC-C18 column (3.0 × 50 mm, 2.7 µm). Sample injections of 20 µL
were made using a 6 port (0.25 mm) Cheminert C2V injection valve (Houston, TX)
incorporated on a dual rail GERSTEL MPS autosampler (Linthicum, MD).
The mobile phase used 0.1% formic acid in water (mobile phase A), and 0.1%
formic acid in acetonitrile (mobile phase B) with a gradient from 95% A for 0.5 min,
ramped to 5% A at 3 min, held at 5% A at 3.5 min, and then changed back to 95% A, for
a run time of 6 min. The eluent was diverted to waste during the intervals of 0-0.75 and
4.5-6 min after the injection. The column flow rate was 0.4 mL/min. Electrospray voltage
was 4000 V, and gas pressure was 60 psi. The selected MRMs were 286.1 to 152.1/165.1
(morphine), 462.0 to 285.8/200.89 (morphine glucuronide), 306.0 to 217.9/164.9/182.9
(codeine-d6), and 327.9 to 165/201.9 m/z (6-MAM).
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Results
Hydrolysis of Spiked 6-MAM Samples
Four enzymes were used to individually hydrolyze a previously drug-free urine sample
spiked with 6-MAM for 0, 1, and 2 h. Nine samples were prepared for each enzyme,
three samples for each length of hydrolysis. Therefore, any conversion could be
monitored as a function of time. Of these four enzymes, three (Haliotis rufescens, Helix
pomatia, and Patella vulgata) resulted in a decrease of 6-MAM and simultaneous
increase in morphine after just 1 h.
The comparison of chromatograms (Figure 2.2) clearly shows that the Helix
pomatia enzyme converts 6-MAM to morphine during the hydrolysis process. The
amount of conversion appears to have a roughly linear relationship with length of
hydrolysis. Over the course of two h. of hydrolysis, 6-MAM area counts decreased by
half and morphine area counts reached a high of almost 11,000.
Figure 2.3 shows data from the analysis of 6-MAM spiked urine samples before
and after hydrolysis with all four of the enzymes: IMCSzymeTM, Patella vulgata (Sigma
Aldrich, St. Louis, MO), Haliotis rufescens (Campbell science), and Helix pomatia
(Sigma Aldrich). The concentration of 6-MAM stayed relatively constant when using
IMCSzymeTM and approximately 10 ng/mL of morphine was detected after two hours.
Because IMCSzymeTM only requires 30 min for glucuronide hydrolysis, any further
morphine production would be minimized. The other enzymes come with
recommendations of two hours for hydrolysis, and significant conversion to morphine
occurs during that time. For example, Haliotis rufescens converted approximately 10% of
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the starting 6-MAM concentration and produced about 28 ng/mL of morphine after two h
of incubation. Patella vulgata converted over 30% of the 6-MAM and 75 ng/mL of
morphine was detected after two h. Most severely, incubation for two h with Helix
pomatia resulted in 47% loss in 6-MAM and a morphine level of 120 ng/mL. The
concomitant 6-MAM loss and morphine increase suggests that the enzyme is responsible
for the conversion.
Hydrolysis of 6-MAM Positive Patient Samples
The hydrolysis procedure used for the control samples was repeated with patient samples
positive for 6-MAM. The exception being that these samples were hydrolyzed using the
manufacturer specified hydrolysis time for each enzyme. (Haliotis rufescens, Helix
pomatia, and Patella vulgata: 2 h; IMCSzymeTM: 30 m). Each patient sample was
analyzed prior to hydrolysis (“Unhydrolyzed”) and was also separated into four different
aliquots to be hydrolyzed with each of the four enzymes. Table 2.1 illustrates the
significant conversion of 6-MAM to morphine in patient samples. The increase in
morphine is unreliable as an indicator for the 6-MAM conversion due to the probable
presence of morphine glucuronides prior to hydrolysis; however, the 6-MAM
concentration should not fluctuate as a result of enzyme hydrolysis. Any variation of 6MAM concentration can thus be attributed to enzyme conversion as shown with the
controlled samples. In the case of Helix pomatia hydrolysis of patient sample 3741,
almost half of the initial detected 6-MAM is lost in the time necessary for the enzyme to
hydrolyze morphine glucuronides (two h). Both Patella vulgata and Haliotis rufescens
also showed significant conversion to morphine, while IMCSzymeTM converted very
little. Patient sample 3637 obviously contained morphine and morphine glucuronides, but
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reduction in 6-MAM was still apparent when Helix pomatia and Patella vulgata enzymes
were used. Lastly, in patient sample 3627, 6-MAM concentrations increased with some
of the enzymes which could possibly be attributed to the presence of acetate buffer as
noted by Heideloff, et al. (11). However, notable morphine increases for Helix pomatia,
Patella vulgata, and Haliotis rufescens occurred.
Conclusion
Significant conversion of 6-MAM to morphine occurs with the use of Helix pomatia,
Patella vulgata and Haliotis rufescens enzymes for morphine glucuronide hydrolysis.
This conversion is seen in the quality control samples as well as the patient samples.
Depletion of 6-MAM to morphine using these enzymes would reduce the likelihood of
detecting conclusive heroin use. IMCSzymeTM demonstrates efficient hydrolysis of
morphine glucuronide with negligible conversion of 6-MAM to morphine. While some
conversion may occur after two h of incubation, only 30 min is needed for optimal
morphine glucuronide hydrolysis with IMCSzymeTM. Conversion of 6-MAM to
morphine should be considered when using β-glucuronidase hydrolysis for analysis of
heroin metabolites.
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Figure 2.1. Metabolic pathway of heroin.
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Figure 2.2. Morphine and 6-MAM intensities after Helix pomatia hydrolysis for 0 hours
(A), 1 hour (B), and 2 hours (C) of 6-MAM spiked drug-free urine.
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Morphine Increase
Concentration (ng/mL)

140
120
100

IMCSzyme

80

Helix pomatia

60

Patella vulgata

40

Haliotis rufescens

20
0
0

1
Time (hours)

2

Figure 2.3. Concentration (ng/mL), of 6-MAM and morphine after 0, 1, and 2 h. of
incubation with the respective enzyme in previously drug free urine spiked with 6-MAM.
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Table 2.1
Concentration (ng/mL) of 6-MAM and morphine in patient
samples, 3741, 3637, and 3627, after hydrolysis of
respective enzyme compared to the unhydrolyzed sample.
Hydrolysis
Unhydrolyzed
IMCSzymeTM
Helix pomatia
Patella vulgata
Haliotis rufescens
Hydrolysis
Unhydrolyzed
IMCSzymeTM
Helix pomatia
Patella vulgata
Haliotis rufescens
Hydrolysis
Unhydrolyzed
IMCSzymeTM
Helix pomatia
Patella vulgata
Haliotis rufescens

3741
6-MAM
91.3
88.6
37.3
71.0
58.8
3637
6-MAM
781.7
743.1
424.4
522.5
801.6
3627
6-MAM
57.2
65.0
73.4
103
103.4
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Morphine
0
1.8
41.1
15.8
14.3
Morphine
4006.3
44042.5
62093.7
51581.1
47031.6
Morphine
0
4.3
48.6
27.4
10.2

CHAPTER 3
INNOVATIVE METHOD FOR MONITORING BENZODIAZEPINES IN MECONIUM:
VALIDATION AND INTERLABORATORY COMPARISON

Abstract
A novel method for the quantitation of ten commonly prescribed benzodiazepines and
metabolites (7-aminoclonazepam, clonazepam, α-hydroxyalprazolam, alprazolam,
nordiazepam, diazepam, midazolam, oxazepam, lorazepam, and temazepam) in
meconium was developed using enzymatic hydrolysis, WAX-S dispersive pipette
extraction (DPX) tips, and liquid chromatography tandem mass spectrometry (LCMS/MS). The method requires only 25 mg of meconium, limits pre-hydrolysis
preparation to a dilution with water, and uses DPX tips for a quick (< 60 s) and effective
sample clean-up post-hydrolysis. Calibrations were linear over a range of 5 ng/g to 1000
ng/g with correlation coefficients above 0.99 for each benzodiazepine. All intraday,
interday, and total imprecision measures were below 13 % RSD. A blind study with a
corresponding laboratory based on 35 positive patient samples produced an R2 value of
0.9206 for quantitative results, and perfect agreement for qualitative results
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Introduction
Benzodiazepines are a schedule IV class of psychotropic drugs commonly used for their
depressant properties (1). Benzodiazepines are one of the most prescribed drug classes to
women of reproductive age and to pregnant women (2, 3). However, the US Food and
Drug Administration (FDA) classifies most benzodiazepines as pregnancy category “C”,
which have shown adverse effects on animal fetus, but there are no studies in humans, or
“D”, which have shown conclusive evidence of negative effects on human fetus (4).
Benzodiazepines have the ability to cross the placenta and accumulate in the fetus,
potentially causing adverse effects such as cleft palates and withdrawal symptoms (2, 46). Maternal prescription, prenatal prescriptions, misuse of non-prescribed medications
and administration during birth to the mother and/or to the newborn are possible sources
of fetal exposure to benzodiazepines. Thus, detection of benzodiazepine use is critical
both for monitoring compliance and misuse/abuse by pregnant women, and for
identifying potential health risks and treatment options for exposed newborns.
Meconium is the black, tarry stool of a newborn passed 1-5 days after birth.
Meconium is an ideal toxicological matrix for identifying in utero drug exposure because
it acts as a repository for xenobiotics including drugs of abuse from the 12-16th week of
gestation until birth (7-9). Drugs accumulate in the meconium as a function of fetal
swallowing of bile or urine and fetal biliary excretion. Once deposited, the meconium and
drugs therein remain fixed until passed after birth, although the potential for drug
degradation has been noted (7).
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Due to its large window of detection and the easy, non-invasive collection,
meconium has become a matrix of choice for determining fetal exposure to drugs (10).
However, analysis of meconium is difficult. Meconium is a complex heterogeneous
mixture composed of epithelial cells, mucus, lanugo, bile acids and salts, sugars, lipids,
proteins, pancreatic and intestinal secretions, and more (1, 7, 9). As a result of this
complexity, use of meconium as a biological matrix to monitor drug use by liquid
chromatography/mass spectrometry is problematic because of the potential for significant
matrix effects. Reducing matrix effects requires sample preparation methods that can
extract target analytes from the endogenous biological interferents, a task that is often
time consuming and labor intensive. Further, benzodiazepines are extensively
metabolized, producing many glucuronide conjugates. Enzymatic hydrolysis with βglucuronidases is employed to convert glucuronides back to the free parent compound for
improved detection (11). Unfortunately, enzyme hydrolysis adds time and complexity to
the analysis of meconium. The objective of our present research is to minimize both
meconium matrix effects and sample preparation time by using minimal sample,
performing hydrolysis in situ, preparing samples with dispersive pipette extraction (DPX)
tips, and analyzing benzodiazepines with liquid chromatography tandem mass
spectrometry.
The method was evaluated for imprecision (total, interday, and intraday),
accuracy, extraction recovery, and linearity, and limits of detection and quantitation were
estimated for each of the ten benzodiazepines and/or metabolites analyzed (7aminoclonazepam, clonazepam, α-hydroxyalprazolam, alprazolam, nordiazepam,
diazepam, midazolam, oxazepam, lorazepam, and temazepam). A blind study of 35
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patient samples was performed with a collaborating lab (ARUP Laboratories, Salt Lake
City, UT) that independently determined benzodiazepine concentrations using alternative
β-glucuronidase hydrolysis, solid phase extraction, and LC-MS/MS.
There are a few publications regarding the analysis of benzodiazepines in
meconium using LC-MS/MS (1, 9, 12), and one paper that reports analysis of meconium
for nicotine, cocaine, and metabolites using DPX tips for sample preparation (13). The
objective of this study was to develop and validate a simple and reliable method for the
analysis of benzodiazepines in meconium using LC-MS/MS.
Experimental
Reagents and Standards.
Drug standards and deuterated internal standards (7-aminoclonazepam, clonazepam, αhydroxyalprazolam, alprazolam, nordiazepam, diazepam, midazolam, oxazepam,
lorazepam, temazepam, 7-aminoclonazepam-d4, midazolam-d4, oxazepam-d5, lorazepamd4, clonazepam-d4, temazepam-d5, and diazepam-d5) were purchased from Cerilliant
Corporation (Round Rock, TX). Fisher Scientific (Waltham, MA) Optima LC/MS grade
acetonitrile and formic acid were used.
DPX WAX-S tips were purchased from DPX Technologies, LLC (Columbia,
SC). IMCSzymeTM was obtained from Integrated MicroChromatography Systems, LLC
(Columbia, SC). Blank meconium, used for all controls and calibrators, was donated by
ARUP Laboratories (Salt Lake City, UT) and previously found to be negative using
established preliminary and confirmatory methods (10). Patient samples for the blind
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study (also donated by ARUP) had been previously analyzed and all patient identification
was removed prior to donation.
Instrumental Analysis.
Analyses were performed using a Thermo TSQ Vantage triple quadrupole system
(Thermo Fisher Scientific Inc, Waltham, MA) with an Agilent 1100 HPLC system
(Agilent Technologies, Santa Clara, CA) equipped with an Agilent Poroshell EC-C18
column (3.0 x 50 mm, 2.7 µm). Sample injections of 20 µL were made using a 6 port
(0.25 mm) Cheminert C2V injection valve incorporated on a dual rail MPS autosampler
(Gerstel Inc., Linthicum Heights, MD).
The mobile phase was composed of 0.1% formic acid in water (A) and 0.1%
formic acid in acetonitrile (B). The initial gradient was 70% A for 0.25 min, which then
ramped to 5% A at 5 min. The gradient remained at 5% A for 1 min, and then switched
back to 70% A for a total run time of 6.5 min. The eluent was diverted to waste during
the intervals of 0-0.5 and 5-6.5 min after injection. The column flow rate was 0.4
mL/min. The electrospray voltage and the gas pressure were set at 4000V and 60 psi,
respectively. Selected multiple reaction monitoring transitions (MRMs) and retention
time windows are listed in Table 3.1.
Methods
Sample Preparation.
Meconium samples were weighed (25 mg) and transferred into 2 mL micro centrifuge
tubes (VWR, Radnor, PA) containing 215 µL of water from an 18.2 MΩ, Millipore
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(Billerica, MA) Direct-Q 3 Ultrapure Type 1 water purification system. The mixture was
vortexed using a Fisher Scientific (Waltham, MA) Vortex-Genie at speed 10 until
homogenously distributed/dissolved in the water. A solution consisting of 75 L of pH
7.5, 0.1 M potassium phosphate buffer, 50 L of IMCSzymeTM β-glucuronidase enzyme
(50,000 units/mL), and 10 L of 500 ng/mL internal standards (7-aminoclonazepam-d4,
midazolam-d4, oxazepam-d5, lorazepam-d4, clonazepam-d4, temazepam-d5, and
diazepam-d5) in water was added. This mixture was then incubated for 1 h at 55°C using
a Labnet VorTempTM 56 Benchtop Incubator/Shaker (Woodbridge, NJ). Following
hydrolysis, 600 L of acetonitrile was added to the mixture to precipitate proteins. This
mixture was vortexed for ~20 s and centrifuged for 5 min using a Becton Dickinson
(Franklin Lakes, NJ) Clay Adams brand Compact II Centrifuge. The supernatant (~950
μL) was removed and placed into a clean round bottom shell glass vial. The solution was
taken in and out of a DPX-WAX-S tip (20 mg 55-65 μm resin/40 mg salt) twice. This
step separates the acetonitrile and water layers and facilitates transfer of analytes into the
acetonitrile supernatant, and binds matrix components to the resin to reduce matrix
effects. The top acetonitrile layer (~500 μL) was then transferred to a new vial suitable
for solvent evaporation. Solvent evaporation was performed with a Sybron
ThermolyneTM Dri-Bath (Barnstead/ Thermolyne Corp., Dubuque, IA) at temperature
setting 8 with N2 gas flow. After evaporation, the residue was reconstituted in 100 L of
10/90 methanol/water (v/v) and analyzed by LC-MS/MS.
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Results and Discussion
Because meconium is available in a finite quantity, minimizing sample mass required for
analysis is desirable to conserve patient specimens for other analyses. Past methods have
used 1 g of meconium and required pre-hydrolysis preparation including mechanical
homogenization and 15 min of centrifugation (1). Our methodology uses 25 mg of
meconium and requires dilution with water and vortexing until homogenized prehydrolysis. Hydrolysis is performed with IMCSzymeTM, which is a genetically
engineered β-glucuronidase enzyme optimized for rapid hydrolysis. Morris, et. al.
previously reported use of IMCSzymeTM for complete hydrolysis of benzodiazepines in
urine in less than 5 min (14). IMCSzymeTM was chosen because it hydrolyzes
benzodiazepines efficiently, and because it is highly purified and will not complicate the
matrix further. Performing the hydrolysis in situ was an important goal to minimize
overall pre-hydrolysis preparation and to avoid protein precipitation prior to hydrolysis.
Protein precipitation can trap analytes of interest in clusters of folded proteins, often
discarded or out of reach of enzyme, reducing the availability of target compounds. If
protein precipitation were performed prior to hydrolysis, an additional solvent
evaporation step would have been required because β-glucuronidases have poor
performance in high organic content solutions. Thus, we proposed hydrolysis with βglucuronidase in situ followed by protein precipitation with acetonitrile for increased
efficiency.
Following hydrolysis and protein precipitation, the supernatant was transferred to
a clean vial, and the solution was extracted using dispersive pipette extraction (DPX).
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DPX is a solid phase extraction method that incorporates loosely contained sorbent in a
pipette tip between a frit at the narrow bottom end of the tip and a barrier at the wider top
end. By using loose sorbent, DPX tips increase surface area available for analyte contact,
which produces high extraction efficiency. The tips allow for simple and fast clean-up
methods, typically taking less than 60 s to complete. In summary, a “dirty” solution is
aspirated into the tip, then air drawn into the tip (to effect vigorous mixing of sample
solution and sorbent), and a clean solution is eluted. The process permits rapid
equilibration and selective retention of the matrix components, leaving the analytes of
interest in the clean eluted solution. In this case, using WAX-S tips, the clean solution
contains 2 layers, with the upper acetonitrile layer containing the analytes with high
recovery.
Method Validation.
Extraction recovery, ion suppression, imprecision (interday, intraday, and total),
analytical measurement range, and limits of detection and quantitation were evaluated to
validate the performance of the method.
Extraction recovery was estimated by comparing three replicate extractions of
fortified samples to three replicate matrix matched (analyte spiked post-extraction)
samples. Three blank meconium samples were fortified with the ten benzodiazepine
standards and then analyzed according to the above procedure. Three blank meconium
samples were also analyzed according to the same procedure, but were fortified just
before solvent evaporation. The samples were fortified to theoretically have the same
final concentration as the pre-fortified samples (i.e., accounting for the total dilution
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factor). These samples are referred to as “matrix matched” samples and represent 100%
recovery. Extraction recovery was calculated by taking the average response in the prefortified samples, dividing by the average response in the matrix matched samples for
each benzodiazepine, and expressed as a percentage. Ion suppression was similarly
calculated, but the matrix matched samples were compared to three “neat” replicates. The
neat replicates did not contain any meconium and were simply the final solvent
composition (100 µL of 10% methanol in water (v/v)) spiked to the same concentration
as the matrix matched samples. The average response in the neat sample was then
compared to the average response of the matrix matched for each benzodiazepine, and
then multiplied by 100 to express ion suppression as a percent. The recovery and ion
suppression percentages for the benzodiazepines of interest are listed in Table 3.2. All
recoveries were greater than 50% (55% to 81%) and percent ion suppression did not
exceed 45% for any analyte, with 7 of the 10 benzodiazepines having less than 20% ion
suppression.
Linearity was assessed by analyzing samples at ten concentration points (5, 10,
25, 50, 75, 100, 250, 500, 750, 1000 ng/g) with four replicates at each point. The
correlation coefficients and subsequent linear regression analysis equations for each
benzodiazepine are shown in Table 3.3. The calibrations for all compounds produced
coefficients of determination (R2) above 0.994 with slopes ranging from 0.9948 to
1.0414. Limit of detection (LOD) and the limit of quantitation (LOQ) estimates for each
benzodiazepine are also listed. LOD was calculated as 3.33 times the standard deviation
of four replicate measurements at the concentration of the lowest non-zero calibrator (5
ng/g) divided by the slope of the calibration line. The LOQ was calculated as 10 times the
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same standard deviation divided by the slope of the calibration line. The LODs ranged
from 0.5 to 2.1 ng/g, and the LOQs ranged from 1.5 to 6.4 ng/g. For ease of use, the LOD
and LOQ were administratively set to 5 ng/g and 10 ng/g, respectively.
A precision study was performed over three days with three replicate samples at
concentrations of 100 ng/g and 1000 ng/g each day, for a total of nine samples at each
concentration. The average intraday imprecision (expressed as percent relative standard
deviation, %RSD) was based on the average of each day’s concentration standard
deviation. The intraday precision did not exceed 10% RSD. The average interday
imprecision was 10.2 % or lower for each benzodiazepine at each concentration. Lastly,
the total imprecision, which is the square root of the sum of the squares of the interday
and intraday imprecision at each concentration for each benzodiazepine, ranged from 2.3
to12.2 % RSD. Values of zero for the interday imprecision represent a negligible
imprecision when compared to the intraday imprecision, thus total imprecision is simply
equal to the intraday imprecision (15).
Case Samples and Blind Study.
Meconium case samples that had been previously analyzed were provided by ARUP.
These patient samples (35 in total, with 89 positive benzodiazepines) were analyzed
using the lab’s existing validated meconium method involving a mechanical
homogenization process, enzyme hydrolysis (post protein precipitation), solid phase
extraction, and a different LC-MS/MS system than used in our work, similar to that
described previously (16). These patient samples were analyzed in our laboratory in
triplicate by our method delineated above. Relative standard deviations (% RSD) for the
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measurements of each benzodiazepine in each set of patient samples ranged from 0.04%
to 40% with an average %RSD of 8%.
The correlation coefficient for measured benzodiazepine concentrations
determined by our method against the previously estimated results determined by the
corresponding lab’s results was 0.9206 (Figure 3.2). Additionally, every benzodiazepine
found in each patient sample by ARUP was also found by our method (100% qualitative
correlation). Further observations concerning individual benzodiazepines are also
possible. Seven out of the ten individual analytes of interest exhibited great correlation
with R2 > 0.93. The three analytes that fell below an R2 of 0.93 were alphahydroxyalprazolam (0.8206), alprazolam (0.8178), and 7-aminoclonazepam (0.4387). 7aminoclonazepam likely had a low correlation due to a low number of positive samples
(n = 6), but a recent presentation suggests it may also be due to degradation during the
time between ARUP analysis and our analysis (17). The presentation reported that 7aminoclonazepam decreased by 48% at 4 °C after storage for two weeks. Lower
correlation of alpha-hydroxyalprazolam and alprazolam may be affected by the lack of
respective internal standard. Seven out of ten of the analytes had slopes ranging from
0.91-1.3, indicating that our results were not systematically higher or lower than the
ARUP previously reported values. The overall success of this blind study validates the
application of this quick and easy method compared to a more intricate, lengthy method.
Conclusions
The method reported here is based on simple vortexing for sample homogenization, use
of fast and reliable IMCSzymeTM for hydrolysis in situ that reduces hydrolysis time to
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one hour, and use of a single WAX-S DPX tip for rapid sample clean-up. The final
extract consists of a clean and analyte rich acetonitrile solution, which is solvent
evaporated and reconstituted in 10% methanol. The method minimizes sample
preparation and solvent evaporation times. LODs and LOQs were below 5 and 10 ng/g,
respectively. Coefficients of determination for the calibrations with each benzodiazepine
were above 0.99 for the ten-point calibration (5-1000 ng/g) with four replicates at each
point. Results from 35 positive patient samples using our method, compared to the results
from our collaborating laboratory using a different analytical protocol, produced an
overall correlation of 0.9206. While the percent recovery and ion suppression outcomes
were not ideal, they are acceptable given the difficult and complex nature of meconium
and the level of precision, linearity, and sensitivity achieved by the method. DPX tip
extraction and the straightforward nature of the method also enables automation of the
sample preparation and analysis protocol. The success of the blind study indicates that
analytical approach espoused herein, consisting of a combination of fast hydrolysis
coupled with a simple clean-up scheme, offers an effective analytical approach for the
analysis of benzodiazepines in meconium.
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Table 3.1
Mass transitions and retention time windows for the ten benzodiazepines and
deuterated internal standards.
Ion mass, Quantifier,
Qualifier, Retention time
Compound
m/z
m/z
m/z
(min)
7-Aminoclonazepam
285.8
249.90
221.90
1.28-1.32
Midazolam
325.7
290.80
208.80
3.23-3.29
α-hydroxyalprazolam
324.7
296.84
175.94
3.49-3.53
Alprazolam
308.8
164.94
280.85
3.65-3.68
Oxazepam
286.7
240.94
268.81
3.66-3.68
Nordiazepam
270.7
139.97
164.93
3.71-3.75
Lorazepam
321.0
274.78
302.77
3.73-3.78
Clonazepam
315.7
269.80
213.90
3.78-3.81
Temazepam
300.7
254.86
282.81
3.99-4.00
Diazepam
284.7
153.97
192.97
4.18-4.20
7-Aminoclonazepam-d4
289.8
121.00
225.90
1.26-1.30
Midazolam-d4
329.7
294.90
247.70
3.23-3.28
Oxazepam-d5
291.7
245.87
287.82
3.65-3.67
Lorazepam-d4
328.9
278.80
306.70
3.72-3.75
Clonazepam-d4
319.7
273.80
217.80
3.78-3.81
Temazepam-d5
305.7
259.87
287.82
3.96-3.99
Diazepam-d5
289.7
153.99
197.96
4.14-4.18

51

Table 3.2
Mean percent recovery and mean percent ion suppression for
benzodiazepines.
Compound
% Recovery
% Ion Suppression
Nordiazepam
60.33
13.21
Diazepam
54.97
27.19
7-Aminoclonazepam
64.23
38.20
Oxazepam
54.51
2.00
Temazepam
63.57
19.73
Alprazolam
80.74
6.54
Clonazepam
68.46
12.98
Lorazepam
56.32
1.69
α-hydroxyalprazolam
80.95
6.03
Midazolam
77.95
42.82
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Relative Abundance

Retention Time (min)

Figure 3.1 A chromatogram of a 100 ng/g spiked meconium sample analyzed according
to the same procedure. Peak identities are: (1) 7-aminoclonazepam, (2) Midazolam, (3) αhydroxyalprazolam, (4) Oxazepam, (5) Alprazolam, (6) Nordiazepam, (7) Lorazepam, (8)
Clonazepam, (9) Temazepam, and (10) Diazepam.
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Table 3.3
Linear regression results and limits of detection and quantitation.
Compound

R2

Equation

7-Aminoclonazepam
Midazolam
α-hydroxyalprazolam
Alprazolam
Oxazepam
Nordiazepam
Lorazepam
Clonazepam
Temazepam
Diazepam

0.9997
0.9965
0.9948
0.9953
0.9956
0.9971
0.9979
0.9993
0.9950
0.9984

y = 0.0048x - 0.0047
y = 0.0043x - 0.0430
y = 0.0003x - 0.0008
y = 0.0038x - 0.0055
y = 0.0031x - 0.0123
y = 0.0037x + 0.0028
y = 0.0014x + 0.0043
y = 0.0051x - 0.0048
y = 0.0039x - 0.0163
y = 0.0059x - 0.0213
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LOD
(ng/g)
1.5
0.5
1.8
1.6
1.2
1.9
2.1
1.4
0.6
0.7

LOQ
(ng/g)
4.4
1.5
5.3
4.8
3.7
5.8
6.4
4.2
1.8
2.1

Table 3.4
Average within-run precision, average between-run precision, and total precision
for two concentrations (100 and 1000 ng/g) expressed in percent relative standard
deviation (%RSD).
Within Run
Between Run
Total Imprecision
Imprecision
Imprecision
Compound
100
1000
100
1000
100
1000
7-Aminoclonazepam
1.8
0.0
2.6
3.9
3.2
3.9
Midazolam
6.4
1.3
0.0
1.6
6.4
2.0
α-hydroxyalprazolam 11.8
10.0
2.9
0.0
12.2
10.0
Alprazolam
5.7
4.5
0.0
1.5
5.7
4.7
Oxazepam
3.3
3.1
2.0
2.5
3.8
3.9
Nordiazepam
6.5
4.8
7.9
2.7
10.3
5.5
Lorazepam
5.0
2.5
3.8
10.0
6.3
10.4
Clonazepam
1.9
2.5
1.2
1.2
2.3
2.8
Temazepam
5.0
2.4
0.0
3.4
5.0
4.2
Diazepam
4.0
3.2
0.7
0.0
4.1
3.2
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Figure 3.2. Correlation of positive patient sample results from the proposed method and
the ARUP method. The fitted straight line is y = 0.9816x + 6.5126, with a coefficient of
determination of R2 = 0.9206.
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CHAPTER 4
ANALYSIS OF Δ9-TETRAHYDROCANNABINOL AND ITS TWO MAIN
METABOLITES IN WHOLE BLOOD USING AUTOMATED DISPERSIVE PIPETTE
EXTRACTION AND LC-MS/MS

Abstract
An analytical procedure was developed and validated for the analysis of Δ9tetrahydrocannabinol (THC) and its metabolites (11-hydroxy-Δ9-tetrahydrocannabinol
(11-OH-THC) and 11-nor-9-carboxy- Δ9-tetrahydrocannabinol (THC-COOH)) in whole
blood using LC-MS/MS. An automated dispersive pipette extraction (DPX) using a
unique liquid-liquid solid-phase extraction was employed on a Hamilton NIMBUS96
platform to extract the analytes of interest. Extraction time was less than 3 min with a
total LC-MS/MS run time of 5.6 min. The method was fully validated in accordance with
the Scientific Working Group of Forensic Toxicology (SWGTOX) guidelines for limit of
detection (0.22 ng/mL THC, 0.25 ng/mL 11-OH-THC and 0.62 ng/mL THC-COOH),
limit of quantitation, carryover, extraction efficiency (93-100%), matrix effects (8-30%),
linearity (0.5-50 ng/mL), within and between-run precision (CV <7.5%), and accuracy
(mean relative bias <5%). An interlaboratory comparison of patient samples in
collaboration with a local forensic toxicology lab method resulted in a correlation
coefficient of 0.9901 between results from the two labs.
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Introduction
Cannabis is the most widely abused illicit drug in the US. According to the National
Survey on Drug Use and Health, 18.9 million people admitted to marijuana use in the
previous month. Between 2007 and 2012, the rate of marijuana use rose from 5.8% to
7.3% (1). As the use of marijuana increases, it becomes more prevalent in clinical and
forensic case work, particularly in impaired driving cases. After legalization in
Washington State in 2015, the percent of cannabinoid positive cases went from 28 to
40% (2). Colorado also reported an increase in cannabinoid positive case samples after
legalization in 2012 (3). The National Highway Traffic Safety Administration (NHTSA)
reported in 2007, that 8.6% of nighttime drivers tested positive for cannabinoids  a rate
almost four times higher than those with blood alcohol levels equal to or above 0.8 g/L
(4). Recent use of marijuana is associated with 2-6 times increased risk of crashing while
driving, depending on dose, than when unimpaired (5). From 1992 to 2009, 20,000 US
drivers involved in fatal car crashes tested positive for cannabinoids (5).
Δ9-Tetrahydrocannabinol (THC) is the main psychoactive ingredient in cannabis
(marijuana). After smoking, THC is rapidly absorbed into the blood stream. THC is
metabolized into two main metabolites, the active metabolite, 11-hydroxy-Δ9tetrahydrocannabinol (11-OH-THC) and the inactive metabolite, 11-nor-9-carboxy- Δ9tetrahydrocannabinol (THC-COOH). THC affects mental processes, ranging from altered
perception of time and distance to hallucinations (6), owing to the risk of use while
driving. Peak THC effects are 20-30 min after use, when blood levels are the highest,
levels are low after 3 h and become baseline after 4 h (7, 8). Blood is routinely the matrix
of choice when determining drug or alcohol impairment. Colorado and Washington states
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have both legalized recreational marijuana use and adopted a 5 ng/mL THC blood
concentration as the driving under the influence of drugs (DUID) level (3, 9).
Unfortunately, blood draws are not done at the “scene” and can take up to hours after the
time of the incident. DUI data shows that 42 and 70% of all cannabinoid-positive traffic
arrests tested below 5 ng/mL THC in blood. Detection and quantification of THC and its
metabolites in blood at low levels (< 5ng/mL) are imperative in determining time of THC
use and potential impairment.
Previously published LC-MS/MS methods for the analysis of THC and its
metabolites in blood require at least 0.25 mL of blood (10), but most require 0.5 mL or
more (6, 11-16) or derivatization (17) to achieve necessary sensitivity. These methods
often necessitate tedious sample preparation, e.g., use of SPE columns (11-13, 15-16),
intricate online SPE (6), or liquid-liquid extraction (10, 14). Our aim was to develop a
method that minimizes sample volume and automates a fast and easy dispersive pipette
extraction procedure to obtain sensitive quantitation of THC, 11-OH-THC and THCCOOH in whole blood using LC-MS/MS.
Experimental Methods
Reagents and Standards.
All drug standards (Δ9-Tetrahydrocannabinol, 11-hydroxy-Δ9-tetrahydrocannabinol, 11nor-9-carboxy- Δ9-tetrahydrocannabinol, Δ9-Tetrahydrocannabinol-d3, and 11-nor-9carboxy- Δ9-tetrahydrocannabinol-d3) were purchased from Cerilliant Corporation
(Round Rock, TX). DPX WAX-S tips were purchased from DPX Technologies, LLC
(Columbia, SC).
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Instrumental Analysis.
Analyses were performed using a Thermo TSQ VantageTM triple quadrupole mass
spectrometer (Milwaukee, WI) coupled to an Agilent 1260 Series HPLC (Agilent
Technologies, Santa Clara, CA) equipped with an Agilent Poroshell EC-C18 column (3.0
× 50 mm, 2.7 µm) with column temperature held at 50 °C. Sample injections of 20 µL
were made using a 6 port (0.25 mm) Cheminert C2V injection valve (Houston, TX)
incorporated on a dual rail GERSTEL MPS autosampler (Linthicum, MD).
The mobile phase was composed of 0.1% formic acid in water (A) and 0.1% formic acid
in methanol (B). The gradient started at 40% B, ramped to 90% B at 1.3 min, and 91% B
at 3.5 min, after which the composition was ramped quickly ramped to 98% B at 3.6 min,
where it remained until 4.6 min and was re-equilibrated to 40% B. The total run time was
5.6 min. Eluent was diverted to waste during the intervals of 0-1.5 min after injection.
The column flow rate was 0.5 mL/min. Mass spectrometer parameters were: electrospray
voltage, 5000 V/-4500V; auxillary gas pressure, 25 psi; sheath gas pressure, 35 psi;
vaporizer temperature was 330 °C, and capillary temperature was 400 °C. Ion transitions
monitored for each compound are listed in Table 4.1.
Sample Preparation.
Aliquots of 100 L of each sample (calibrator, control, blank, patient sample) were
transferred to a 2 mL micro centrifuge tube (VWR, Radnor, PA). Internal standard in
methanol was added (10 µL) and the tubes were vortex mixed. Acetonitrile (300 µL) was
added and the tubes were vortexed using a Fisher Scientific (Waltham, MA) VortexGenie at speed 10 and then centrifuged for 10 min at 13,300 RPMs using a Thermo
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Scientific Sorvall Legend Micro 17 centrifuge (Milwaukee, WI). For the interlaboratory
comparsion, the forensic samples were prepared up to protein precipitation at the State
Law Enforcement Division to avoid any biological hazards at the University of South
Carolina. The protein precipitated forensic samples were brought back to the university
for centrifugation and further analysis. The supernatant (350 µL) was transferred to a 2.2
mL well plate, which was then placed on the Hamilton NIMBUS96 system (Reno, NV)
for the automated solid-phase extraction procedure. The NIMBUS system was loaded
with DPX WAX-S tips (10 mg WAX resin and 20 mg salt), 300 µL CO-RE tips, a
reservoir of 0.1 M formic acid, and an additional empty well plate. The NIMBUS system
uses the CO-RE tips to add 50 µL of 0.1 M formic acid to the well plate containing the
sample supernatant. The 1 mL DPX WAX-S tips are then used to aspirate and dispense
the sample solution three times, thus allowing extraction of matrix and subsequent
partitioning of the acetonitrile and the aqueous phase. The CO-RE tips are used to
transfer 100 µL of the supernatant (acetonitrile layer) to a clean well plate, which is then
transferred to the LC-MS/MS for injection.
Method Validation
Linearity and Sensitivity.
The method was validated according to SWGTOX guidelines (18). Linear least squares
regression with a 1/x weighting was used as a calibration model for each analyte and
spanned 0.5 ng/mL to 50 ng/mL with seven calibration points and five replicates at each
point. Carryover was evaluated by running an extracted blank matrix sample after each
high calibrator (n = 5). The sensitivity was determined by calculating the limits of
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detection and quantitation. The limit of detection (LOD) was calculated using the
standard deviation of the y-intercept (sy) and the average slope (avgm):
LOD = (3.3 sy)/avgm
The limit of quantitation (LOQ) was similarly quantified with a multiple of 10 instead of
3.3. The average slope and standard deviation of the y-intercept were taken from the five
separate runs of the calibration plot.
Accuracy and Precision.
The accuracy and precision of the method were determined by evaluating three different
concentrations (2 ng/mL, 10 ng/mL, and 25 ng/mL) in triplicate over 5 separate runs. The
accuracy was calculated as the (mean concentration measured – fortified concentration)
divided by the fortified concentration × 100%. The within-run precision was determined
by taking the standard deviation of a single run of samples at a single concentration
divided by the mean calculated value of that single run × 100%. The between-run
precision was determined by taking the standard deviation of all observations for each
concentration divided by the grand mean for each concentration × 100%.
Extraction Efficiency and Matrix Effects.
Matrix effects were determined using the post-extraction addition technique. An
unextracted neat solution of a low concentration (1 ng/mL 11-OH-THC, 5 ng/mL THC,
and 10 ng/mL THC-COOH) and a high concentration (2 ng/mL 11-OH-THC, 20 ng/mL
THC, and 40 ng/mL THC-COOH) were injected six times each (set 1). These results
were compared to pooled blank blood spiked with analyte at the appropriate
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concentration post-extraction in triplicate (set 2). Matrix effects were then calculated as
the mean area of set 2 divided by the mean area of set 1 subtracted from 1 and multiplied
by 100%. A negative value represents ion suppression, while a positive value represents
ion enhancement. Extraction efficiency was determined by comparing the matrix
matched samples (set 2) to a set of samples that were fortified after protein-precipitation
and centrifugation, but before extraction (set 3). Extraction efficiency was calculated as
the mean area of set 3 divided by the mean area of set 2 multiplied by 100%. Finally, loss
during the protein precipitation step was also determined. In this case, the postprecipitation spiked samples (set 3) were compared to a set of samples where the blood
was fortified before any processing (set 4). Protein precipitation loss was also calculated
as the mean area of set 4 divided by the mean area of set 3 × 100%.
Results and Discussion
LC-MS/MS parameters.
Various liquid chromatography and mass spectrometry parameters were evaluated, but
the most noteworthy differences involved the spray voltage and the choice of organic
mobile phase. The difference in analyte signal when switching from low (3500/-3500V)
to high (5000/-4500V) spray voltage was significant. The 11-THC-OH analyte showed
the largest difference with a 2.5-fold increase in signal intensity after switching from low
to high voltage. Similarly, the THC peak doubled in intensity, but the THC-COOH peak
showed a 33% increase. The change of organic mobile phase (B) from acetonitrile to
methanol also resulted in significant increases in signal intensity for all analytes. The 11THC-OH peak exhibited the largest signal increase of over 8 ×. The THC signal
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increased by almost 4 times, and THC-COOH signal increased by about 2.5 times. The
reduced surface tension of methanol and the increased spray voltage both helped to
increase ionization efficiency, with a concomitant increase in both signal intensity and
sensitivity.
Stability in Plastic Time Study.
It is well known that THC has a tendency to fall out of solution and/or be retained on the
surfaces of its container, particularly plastic. In the method presented here, plastic well
plates were utilized throughout sample preparation. Most importantly, plastic well plates
hold the eluent during LC-MS/MS analysis. With a run time of 5.6 min, a full well plate
could take 9 h. A study was performed to evaluate analyte loss due to the use of plastic
well plate containers at room temperature in the eluent conditions (~100% acetonitrile).
Samples were extracted in triplicate at three different concentrations (1, 10, 25 ng/mL)
for each analyte. The extracted samples were injected immediately at time 0, and then
again at 6, 12, and 24 h. Concentrations did not vary by more than 15% except at 1
ng/mL for THC-COOH, which decreased by 35% after 12 h; however, no further loss
was observed at 24 h. As a result of this study, well plates were used throughout this
study, but calibrators were re-injected at the end of the runs to ensure stability.
Linearity and Sensitivity.
Calibration fitting resulted in average coefficients of determination (R2) values of 0.9984
for THC, 0.9980 for 11-OH-THC, and 0.9966 for THC-COOH. The average slope and yintercept standard deviation values were used to determine the LODs and LOQs for each
compound (0.66 ng/mL for THC, 0.75 ng/mL for 11-OH-THC, and 1.8 ng/mL for THC-
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COOH) as described above (Table 4.2). The limit of quantitation for each compound was
well below the recommended cut-off level for DUID confirmation in blood of 1, 5, and 1
ng/mL for THC, THC-COOH, and 11-OH-THC, respectively (19). Chromatograms of
the parent-to-quantifier transition response for each of the analytes at the suggested cutoff levels are shown in Figure 4.1.
Accuracy and Precision.
Accuracy, within-run precision, and between-run precision were determined and shown
in Table 4.3. The method exhibited a minimum bias of 0.02% at 25 ng/mL for 11-OHTHC, and a maximum of 4.7% at 2 ng/mL of THC. The within-run and between-run
precision was ascertained from the same replicate analyses. The average within-run
precision had a maximum of 6.8% at 2 ng/mL of THC, and the between-run precision
had a maximum at 2 ng/mL of THC at 7.5%.
Extraction Efficiency and Matrix Effects.
Low concentrations of analyte are most susceptible to large matrix effects. Ion
suppression for THC was 31% at 5 ng/mL, but only 12% at 20 ng/mL. The 11-OH-THC
analyte elicited ion suppression at 1 ng/mL of 6% and 2% at 2 ng/mL. THC-COOH had
negligible matrix effects, showing ion suppression at 10 ng/mL of 3% but ion
enhancement at 40 ng/mL of 3%. The DPX extraction post-protein precipitation was very
efficient at >93% at both concentrations for all compounds. The loss of analyte during the
protein precipitation step also varied with concentration. There was approximately 30%
loss of all compounds at 25 ng/mL, but 15%, 19%, and 8% of THC, 11-OH-THC and
THC-COOH, respectively, were lost at 2 ng/mL.
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Interlaboratory Comparison.
A successful sample comparison was completed with the South Carolina Law
Enforcement Division (SLED). SLED uses a method that requires 1 mL of blood and
employs solid-phase extraction cartridges and GC-MS analysis. Twenty-eight forensic
samples were compared. Each sample was analyzed in triplicate using the DPX method
described above. The coefficient of determination (R2) for the comparison of 11-OHTHC positive samples was 0.9965 (n = 3) (Figure 4.2), THC-COOH R2 was 0.9836 (n =
27) (Figure 4.3), and THC produced an R2 of 0.9960 (n = 16) (Figure 4.4). When all
positive results were combined, the overall correlation was 0.9901 (Figure 4.5). A
chromatogram of the parent to quantifier ion transitions for each of the analytes in patient
sample 13 is shown in Figure 4.6. The calculated percent difference in triplicate analysis
of each sample compared to the reported concentration from SLED did not exceed 20%
for any case sample. The relative standard deviation of the triplicate extractions of patient
samples did not exceed 15%. SLED detection cut-off values were 2 ng/mL for each
analyte. Our LOQs were considerably lower and resulted in more positive 11-OH-THC
and THC samples than SLED identified.
Conclusion
The LC-MS/MS method developed in this study minimizes required sample volume, and
provides sensitive quantitation of THC, 11-OH-THC and THC-COOH in whole blood.
Notably, our method simplifies sample preparation for the analysis of THC and its
metabolites in blood with an automated dispersive pipette extraction without subsequent
dilution or solvent evaporation. The extraction process is rapid, minimizes matrix effects
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(<30%), and maximizes recoveries (>93%). LODs and LOQs were below 0.75 ng/mL
and 2 ng/mL, respectively. These outcomes clearly provide the necessary sensitivity to
meet laboratory cut-off with minimal imprecision (<8%). All calibrations were linear (R2
> 0.99) over two orders of magnitude (0.5-50 ng/mL). Lastly, a successful comparison of
forensic case sample using our new method with a local toxicology laboratory verifies the
effectiveness of this new quick and easy method.
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Table 4.1. Selected ion transitions
Compound
Precursor
Quantifier
343
299.06
THC-COOH
346
301.89
THC-COOH d3
331
312.99
11-OH-THC
THC
315
192.98
THC d3
318
196.00

71

Qualifier
244.99
N/A
193.10
123.03
N/A

Table 4.2. The standard deviation of the y-intercept (Sy), average slope (n=5)
(Avgm), limit of detection (LOD) in ng/mL, limit of quantitation (LOQ) in
ng/mL, and the average coefficient of determination (R2) (n = 5).
Sy
Avgm
LOD
LOQ
Avg R2
0.001
THC
0.014
0.22
0.67
0.9984
11-OH-THC
0.006
0.074
0.25
0.75
0.9980
0.003
THC-COOH
0.016
0.62
1.8
0.9966
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Table 4.3. The accuracy, within-run precision,
and between-run precision calculated as
described above.
Accuracy
2 ng/mL 10 ng/mL 25 ng/mL
THC
4.7%
0.7%
-0.2%
11-OH-THC
-1.3%
-2.8%
0.02%
THC-COOH
3.6%
0.7%
-0.4%
Within-Run Precision
2 ng/mL 10 ng/mL 25 ng/mL
THC
6.8%
4.6%
2.8%
11-OH-THC
5.0%
3.5%
1.8%
THC-COOH
6.4%
4.5%
3.0%
Between-Run Precision
2 ng/mL 10 ng/mL 25 ng/mL
THC
7.5%
5.6%
2.9%
11-OH-THC
6.6%
6.0%
3.5%
THC-COOH
7.0%
4.4%
3.1%
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Table 4.4. Extraction efficiency, precipitation loss and matrix effects percentages
for THC, 11-OH-THC, and THC-COOH at multiple concentrations.
Extraction Efficiency
Precipitation Loss
Matrix Effects
Concentration 2 ng/mL 25 ng/mL 2 ng/mL 25 ng/mL
Low
High
THC
94
99
15
30
-31
-12
11-OH-THC
100
99
19
28
-6
-2
THC-COOH
93
96
8
29
-3
+3
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Figure 4.1. Chromatograms of calibrators at previously reported suggested cut-offs for
THC (1 ng/mL), THC-COOH (5 ng/mL), and 11-OH-THC (1 ng/mL).
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SLED Method (ng/mL)

11-OH-THC
7
6
5
4
3
2
1
0
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y = 0.9072x + 0.4672
R² = 0.9965
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4.000

6.000

8.000

DPX Method (ng/mL)

Figure 4.2. Correlation of 11-OH-THC positive case samples between the SLED and
DPX method.
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SLED Method (ng/mL)

THC-COOH
50
y = 0.8809x + 0.5358
R² = 0.9836

40
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50.000
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Figure 4.3. Correlation of THC-COOH positive case samples between the SLED and
DPX method.
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THC
SLED Method (ng/mL)

30
25

y = 0.8545x + 0.6501
R² = 0.996

20
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10
5
0
0.000

5.000
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Figure 4.4. Correlation of THC positive case samples between the SLED and DPX
method.
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Figure 4.5. Correlation of all positive case samples between the SLED and DPX method.
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Figure 4.6. Chromatogram of patient sample 13 with 31 ng/mL THC, 77 ng/mL THCCOOH, and 6.7 ng/mL 11-OH-THC.
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Table 4.5.
Patient Sample (PS) Results in ng/mL ± standard deviation (n = 3).
11-OH-THC
THC-COOH
THC
PS
DPX
SLED
DPX
SLED
DPX
SLED
1
21.5 ± 0.42
21
2.6 ± 0.24
2.4
2
15.3 ± 0.47
14
4.2 ± 0.61
4
3
8.7 ± 0.59
8.6
4
4.7 ± 0.15
4.8
5
2.7 ± 0.29
2.8
37.6 ± 0.95
31
4.9 ± 0.36
5.3
6
44.6 ± 0.47
39
4.1 ± 0.29
4.3
7
24.0 ± 0.73
21
6.4 ± 0.18
6.6
8
12.4 ± 0.49
11
9
20.6 ± 1.2
18
10
3.5 ± 0.24
3.8
27.0 ± 2.0
24
4.8 ± 0.21
4.7
11
4.6 ± 0.20
3.8
12
17.0 ± 0.63
17
13
6.7 ± 0.22
6.5
77.0 ± 2.6
>50
31.0 ± 2.3
27
14
6.4 ± 0.29
7.5
15
2.8 ± 0.28
2.9
16
19.4 ± 1.1
18
2.32 ± 0.15
2.1
17
22.6 ± 0.38
20
5.9 ± 0.26
6.2
18
16.4 ± 1.4
14
3.3 ± 0.41
3.8
19
12.8 ± 0.78
12
20
38.0 ± 2.2
32
21
76.0 ± 0.41
>50
2.77 ± 0.22
2.6
22
28.0 ± 0.38
23
2.4 ± 0.18
2.3
23
63.4 ± 0.64
>50
3.8 ± 0.27
4.4
24
<2
<2
25
46.5 ± 0.77
45
2.8 ± 0.56
2.7
26
11.4 ± 0.23
11
4.8 ± 0.34
4.9
27
2.8 ± 0.34
2.7
28
33.2 ± 0.77
33
3.5 ± 0.19
3.6
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CHAPTER 5
AUTOMATED DISPERSIVE PIPETTE EXTRACTION OF DIPHENYL BORINATE
COMPLEXED FREE CATECHOLAMINES AND METANEPHRINES IN URINE WITH
LC-MS/MS ANALYSIS

Abstract
The measurement of free catecholamines and metanephrines in the clinical laboratory is
important for the diagnosis of tumors, such as pheochromocytoma, a cancer of the
adrenal gland. We have developed an automated, high throughput procedure, with a short
LC-MS/MS analysis time, for the selective extraction of norepinephrine, epinephrine,
dopamine, normetanephrine, and metanephrine in urine. An automated, high throughput
extraction was achieved using dispersive pipette extraction (DPX) tip technology on an
automated sample preparation system. The method was assessed for linearity, sensitivity,
precision, accuracy, carryover, matrix effects and recovery. Using diphenyl boronic acid
for complexation and styrene divinyl benzene for extraction enabled high recoveries
(>81%) and reduced ion suppression (<39%). A pentafluorophenylpropyl column was
found to provide adequate chromatographic separation prior to analysis on a triple
quadrupole mass spectrometer with positive electrospray ionization. The method was
linear over a broad range from 0.5 ng/mL to 1000 ng/mL, with precision below 8% CV,
and limits of detection below 0.25 ng/mL for all analytes. External quality controls were

82

tested and quantitative results fell within the manufacturer specified concentration ranges.
The simple and high throughput nature of this method would be ideal for clinical
laboratories experiencing high demand for catecholamine and metanephrine urine
analysis.
Introduction
The catecholamines, epinephrine, norepinephrine, and dopamine, are bioamines that play
an integral role as neurotransmitters in the central and peripheral nervous system.
Screening for catecholamines and their O-methylated metabolites, metanephrine and
normetanephrine, is a widely accepted approach for diagnosis of catecholamine secreting
tumors, such as pheochromocytomas, neuroblastomas, and paragangliomas (1-5). These
tumors arise from adrenal and extra-adrenal chromaffin cells and are characterized by the
over-production of catecholamines (6). Generally, pheochromocytomas are benign, but
the potent effects on the cardiovascular system caused by excess catecholamines can have
potentially fatal outcomes (7). Correct and timely diagnosis is crucial. Unlike analysis in
plasma, it is recommended that both metanephrines and catecholamines be measured in
urine (8). Urine analysis is not necessarily invasive, and urine usually exhibits
sufficiently high levels of the target compounds. Catecholamines and metanephrines
undergo phase II metabolism, primarily via sulphation. Whiting, et al. reported one-third
of norepinephrine and one-half of epinephrine in urine were present in the free form,
while metanephrines were present in the free form to a lesser extent (8). Previously, acid
hydrolysis has been used to assess the amount of total catecholamine and metanephrines
in urine to boost sensitivity. However, free fractionated metanephrines have been
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proposed for enhanced diagnostic accuracy (9); with LC-MS/MS, methods for
quantitation of free metanephrine have been implemented (5-6).
Catecholamines are characterized by a monoamine-linked benzene ring with two
vicinyl hydroxyl groups (catechol) (2). Epinephrine is a secondary amine, while
norepinephrine and dopamine are primary amines. The catechol group makes the
catecholamines vulnerable to oxidation to the quinone species in neutral and alkaline
conditions (10). Metanephrines do not have the catechol group, but have a methoxy
group adjacent to a hydroxyl group, and are thus more stable. These compounds are
highly polar and hydrophilic, with negative log D and log P values (3). These structural
properties make sample preparation and analysis difficult.
A wide range of sample preparation techniques have been employed to analyze
catecholamines and metanephrines in urine, most have been summarized in a recent
review (3). Cation exchange mechanisms work well for metanephrines, but not the
catecholamines because of their susceptibility to oxidation during elution with base. Solid
phase extraction (SPE) with phenyl boronic acid (PBA SPE) columns work well for
sample preparation of catecholamines because catechol groups bind with high affinity to
the boronic acid groups to provide high recoveries. However, PBA SPE does not work
well with metanephrines due to the absence of catechol groups. A method comparison
published by Whiting, et al. reported reduced recoveries for catecholamines using cation
exchange SPE, and no recovery for metanephrines on PBA SPE (8). The SPE method
with the highest reported recoveries was that developed by Talwar, et al. (11), who found
diphenyl boronic acid (DPBA) to complex and stabilize catecholamines in basic solution.
The complex was then extracted using C18 sorbent, followed by acidic media to disrupt
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the complex and elute the target compounds. DPBA forms reversible covalent bonds with
the catechol of the catecholamines in basic solution; effectively minimizing oxidation and
increasing lipophilicity for reversed phase retention (Figure 5.1). Whiting, et al., also
note that, although metanephrines do not have the cis-diol moiety necessary for the
complexation with DPBA, they exhibited high recoveries with the same extraction
procedure. Metanephrine recovery was decreased by a third without DPBA present
during extraction, suggesting interaction as an affinity-pairing agent. We have adapted
the Whiting method to design a DPX extraction that takes place within a pipette tip,
which facilitates an easily automated alternative to traditional SPE requiring less sample
and solvent volume. The objective of this study was to develop an automated sample
preparation method utilizing the DPBA complexing agent to minimize sample
preparation time (<15 min) and improve sensitivity (limit of detection < 0.25 ng/mL) for
the analysis of free catecholamines and metanephrines in urine with LC-MS/MS.
Experimental Methods
Reagents and Standards.
Drug standards (catecholamine mix 1, catecholamine mix 2, dopamine, dopamine-d4,
norepinephrine-d6, epinephrine-d6, normetanephrine-d3, and metanephrine-d3) were
purchased from Cerilliant Corporation (Round Rock, TX). Ammonium chloride and
diphenylborinic acid 2-aminoethyl ester (98%), were purchased from Acros Organics
through Thermo Fisher Scientific (NJ). LC-MS grade formic acid was also purchased
from Thermo Scientific (Waltham, MA). Level 1 and level 2 ClinChek® lyophilized
biogenic amine urine controls were purchased from RECIPE (Munich, Germany).
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Synthetic urine (SurineTM) was purchased from DTI (Lenexa, KS). DPX CO-RE RP tips
were purchased from DPX Technologies, LLC (Columbia, SC).
Instrumental Analysis.
Analyses were performed using a Thermo TSQ VantageTM triple quadrupole mass
spectrometer (Milwaukee, WI) coupled to an Agilent 1260 Series HPLC (Agilent
Technologies, Santa Clara, CA) equipped with a Restek 3 m Ultra PFPP column (100
mm × 2.1 mm) (Bellefonte, PA) with column temperature held at 40 °C. Sample
injections of 10 µL were made using a 6 port (0.25 mm) Cheminert C2V injection valve
(Houston, TX) incorporated on a dual rail GERSTEL MPS autosampler (Linthicum,
MD).
The mobile phase was composed of 0.1% formic acid in water (A) and 0.1% formic acid
in methanol (B). The gradient started at 4% B and was held for 2 min. It was ramped to
70% B at 3 min, where it remained until 3.75 min, then re-equilibrated to 4% B, for a
total run time of 5.5 min. Eluent was diverted to waste during the intervals of 0-0.5 and
4.0-5.5 min. The column flow rate was 0.3 mL/min. Mass spectrometer parameters were:
electrospray voltage, 3000 V; auxillary gas pressure, 8 psi; sheath gas pressure, 30 psi;
vaporizer temperature was 325 °C and capillary temperature was 300 °C. The transitions
monitored for each compound are listed in Table 5.1. The most abundant m/z was
monitored, which for norepinephrine, normetanephrine and metanephrine was the waterloss (M+H-H2O) product ion.
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Sample Preparation.
In a well plate, 300 µL of synthetic urine, 0.2 M HCl calibrator, or quality control sample
was spiked with internal standard (10 µL). The well plate was loaded onto a Hamilton
NIMBUS96 system. Reservoirs of complexing agent (0.2% (w/v) diphenylborinic acid, 5
g/L EDTA in a 2 M NH4Cl/NH4OH pH 8.5 buffer), wash buffer (0.2 M NH4Cl/NH4OH
pH 8.5), 100% methanol, and 1 M formic acid were also added to the deck of the
Hamilton system. The liquid handling system used CO-RE 1 mL tips to add 600 µL of
complexing agent to the urine sample well plate, 500 µL of wash buffer to a second
“wash” well plate, 270 µL of 1 M formic acid to a third “elution” well plate, and 30 µL
of methanol to the third “elution” well plate. The Hamilton robotic system discards the
CO-RE tips and picks up 1 mL DPX RP (reverse phase) tips. Styrene divinyl benzene
sorbent DPX RP tips are ideal for extracting these analytes. After conditioning by
aspirating and dispensing 100% methanol twice, the tips were conditioned with wash
buffer, and then the sample solution was aspirated and dispensed four times. Note that the
DPBA complexing is essentially quantitative (8), and the mixing provided by aspirating
and dispensing the sample solution insures complexation of catecholamines and efficient
retention on the styrene divinyl benzene resin. After rinsing the tips with the wash buffer,
analytes were eluted with the 1 M formic acid/10% methanol solution. The acidic
solution reverses the diphenyl boronate complexes, and the methanol enhances elution of
any remaining retained analytes via reverse phased interactions. Low methanol content is
also beneficial for minimal removal of any retained matrix and maximizing selectivity.
The “elution” well plate was then moved to the autosampler for LC-MS/MS injection.
This automated process takes less than 15 min to complete.
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Method Validation
Linearity and Sensitivity.
Linear least squares regression with a 1/x weighting was used to fit calibration models
based on nine calibration points for each analyte spanning the concentration range from
0.5 ng/mL to 1000 ng/mL for norepinephrine and epinephrine, and 0.1 to 1000 ng/mL for
dopamine, normetanephrine and metanephrine. Carryover was evaluated by running three
replicate blank samples after each high calibrator. The limit of detection (LOD) was
calculated using the estimated standard deviation of the y-intercept (sy0) and the average
slope of the calibration (avgm):
LOD = (3.3 sy)/avgm
The limit of quantitation (LOQ) was similarly estimated with a multiple of 10 instead of
3.3. The average slope and standard deviation of the y-intercept were taken from the
analysis of three separate sets of extracted calibrators.
Accuracy and Precision.
The accuracy and precision of the method were determined by evaluating two external
quality controls. The Level 1 control had mean values of 64 ng/mL for norepinephrine,
20 ng/mL for epinephrine, 194 ng/mL for dopamine, 325 ng/mL for normetanephrine,
and 172 ng/mL for metanephrine. Level 2 had mean values of 174 ng/mL for
norepinephrine, 39.8 ng/mL for epinephrine, 293 ng/mL for dopamine, 1568 ng/mL for
normetanephrine, and 1017 ng/mL for metanephrine. Each control was analyzed in
triplicate over three separate runs. The accuracy was calculated as shown below.
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(mean concentration measured – fortified concentration)
𝑥 100%
fortified concentration
The within-run precision was determined by taking the standard deviation of a single run
of triplicate quality control samples at a single concentration divided by the mean
calculated value of that single run x 100%. The between-run precision was determined by
taking the standard deviation of all observations (9 total) for each concentration divided
by the grand mean for each concentration x 100%.
Extraction Efficiency and Matrix Effects.
Matrix effects were determined using a post-extraction addition technique. An
unextracted neat solution of 100 ng/mL of each analyte was injected four times (set 1).
These results were compared to the results from four replicate samples of extracted
synthetic urine spiked containing analyte at the appropriate concentration post-extraction
(set 2). Matrix effects were calculated as the mean area of set 2 divided by the mean area
of set 1 subtracted from 1 and multiplied by 100%. A negative value represents ion
suppression, while a positive value represents ion enhancement. Extraction efficiency
was determined by comparing the matrix matched samples (set 2) to a set of synthetic
urine samples that were fortified before extraction (set 3). Extraction efficiency was
calculated as the mean area of set 3 divided by the mean area of set 2 multiplied by
100%.
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Results and Discussion
Chromatography.
Figure 2 shows the separation of the analytes at a concentration of 10 ng/mL. The five
analytes were easily separated on the 100 mm PFPP column. The highest water mobile
phase percentage for initial conditions is ideal to promote the most retention and
separation of these highly polar compounds. With the initial gradient conditions of
methanol (mobile phase B) less than 4%, peak splitting arose due to the relatively large
injection volume (10 uL) of the 10% methanol eluent. The initial gradient conditions
were modified to prevent peak splitting of norepinephrine, and in some cases
epinephrine. Larger initial methanol mobile phase percentages resulted in less separation
between analytes and more interference peaks.
Sample pH and flow rates.
As previously reported by Talwar, et al, the pH of the complexed sample needs to be
within the range of 7.5-9.5 to achieve reproducible high recoveries (> 81%). Sample
loading and elution flow rates also affected recoveries. During aspiration and dispensing
of each step of the extraction process, a slow flow rate was used to assure efficient
mixing of the solution and the sorbent inside the tip. During dispensing steps especially, a
slow flow allows the resin to settle first so the solution flows through the bed of resin at
the bottom of the tip to maximize retention/elution. Higher flow rates resulted in
inconsistent, lower recoveries.
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Elution step.
Formic acid (1 M) was chosen for the elution step from DPX yielded better analyte signal
intensities than acetic acid. While the acid disrupts the diphenyl boronic acidcatecholamine complex, residual reversed phase interactions between free
catecholamines (and metanephrines) with the styrene divinyl benzene sorbent remained.
Addition of methanol was necessary for disrupting the remaining reversed phase
interactions to enhance elution efficiency and thus, enhance recovery. The addition of
methanol to the elution solvent increased recoveries of all analytes with 10% performing
better than 5%.
Linearity and Sensitivity.
Calibrations resulted in average coefficients of determination (R2) values of 0.9992 for
norepinephrine, 0.9996 for epinephrine, 0.9996 for dopamine, 0.9998 for
normetanephrine, and 0.9982 for metanephrine. The average slope and y-intercept
standard deviation values were used to determine the LODs and LOQs for each
compound as described above and shown in Table 5.2. The limit of quantitation for each
compound was similar to or better than those recently reported values (4-7, 12).
Accuracy and Precision.
Accuracy, as well as within-run and between-run precision (% CV) are provided in Table
5.3. The method was very accurate for quantitation of quality control samples with each
average analyte concentration falling within the manufacturer’s listed expected range of
concentrations. The average within-run precision had a maximum CV of 6% for the level
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1 of epinephrine control, and the between-run precision had a maximum CV of 7% for
the level 2 metanephrine control.
Extraction Efficiency and Matrix Effects.
Matrix effects were relatively low for epinephrine, dopamine, normetanephrine and
metanephrine with a range of ion suppression from 1-14%. Norepinephrine exhibited
greater matrix effects with ion suppression at 39%, likely because it is the most polar
compound with little to no retention on the PFPP column. Extraction efficiencies were
higher than 96% for all analytes except dopamine, which resulted in 81% extraction
recovery (Figure 3.3).
Conclusions
We report a fast and robust analytical method reported that achieves sensitive LCMS/MS analysis of free catecholamines and metanephrines in urine. Extraction using
dispersive pipette extraction with DPX tips facilitates seamless integration of SPE with
the Hamilton NIMBUS96 platform for the rapid (< 15 min) extraction of DPBA
complexed catecholamines and metanephrines from urine. This method provides the
necessary sensitivities without an additional solvent evaporation step. Limits of detection
for all analytes were below 0.25 ng/mL, and LOQs were below 0.70 ng/mL. The
calibration was linear (R2 > 0.998) over more than four orders of magnitude with
concentrations ranging from 0.5-1000 ng/mL. Replicate analysis of two different levels
of synthetic urine controls demonstrated % coefficients of variation less than 8%. This
method is an excellent alternative to previously published methods, with the advantages
of ease of implementation, robustness, high sensitivity due to effective sample clean-up,
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and high throughput (96 samples extracted in less than 15 min) with a 5.5 min LCMS/MS run time.
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Figure 5.1. Diphenyl boronate-catecholamine complex structure. (For norepinephrine:
R1 = OH, R2=H; for epinephrine: R1=OH, R2=CH3; for dopamine: R1=H, R2=H).
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Table 5.1. Selected ion transitions
Compound
m/z
Quantifier
Norepinephrine
151.8
106.8
Norepinephrine-d6
157.8
80
Epinephrine
183.9
166
Epinephrine-d6
190.1
171.7
Dopamine
153.8
136.8
Dopamine-d4
157.9
140.7
Normetanephrine
165.8
121
Normetanephrine-d3
168.8
136.7
Metanephrine
180
148
Metanephrine-d3
182.8
120.9
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Qualifier
77
111
107
90.9
133.8
122.8
165
150.8

Table 5.2. The standard deviation of the y-intercept (sy), average
slope (n=5) (avgm), limit of detection (LOD) in ng/mL, limit of
quantitation (LOQ) in ng/mL, and the average coefficient of
determination (R2) (n = 5).
Compound
sy
avgm LOD LOQ avg R2
Norepinephrine
0.0037 0.068 0.18 0.53 0.9992
Epinephrine
0.0058 0.088 0.22 0.65 0.9996
Dopamine
0.0055
0.12 0.15 0.46 0.9996
Normetanephrine
0.00019 0.19 0.003 0.01 0.9998
Metanephrine
0.0016
0.17 0.03 0.09 0.9982
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Table 5.3. Accuracy and Precision of the method based on two levels of external
quality control.
Level 1
Expected
Within-run,
Between Run,
Analyte
Mean
Range
CV
CV
Norepinephrine
51.2-76.8
62.8
5%
5%
Epinephrine
16.0-24.0
19.6
6%
5%
Dopamine
155-233
186.2
3%
6%
Normetanephrine
260-390
264.5
5%
5%
Metanephrine
138-206
166.6
5%
7%
Level 2
Expected
Within-run,
Between Run,
Analyte
Mean
Range
CV
CV
Norepinephrine
139-209
168.3
3%
5%
Epinephrine
31.8-47.8
39.7
2%
2%
Dopamine
234-352
284.3
4%
5%
Normetanephrine
1254-1882
1493.7
4%
4%
Metanephrine
814-1220
1056.8
3%
4%
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Figure 5.2. Separation of analytes at 10 ng/mL: (A) norepinephrine; (B) epinephrine; (C)
normetanephrine; (D) is dopamine; and (E) metanephrine.
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Figure 5.3. Recovery and matrix effects of catecholamines and metanephrines extracted
using the automated DPX method.

101

CHAPTER 6
EVALUATIONS OF LIMIT OF DETECTION, WEIGHTED LEAST SQUARES
REGRESSION, AND TOLERANCE INTERVALS IN A FORENSIC APPLICATION

Abstract
Limit of detection (LOD) is an important figure of merit, especially in forensic science
where the question of detection has real world implications. However, ambiguity often
exists in the choice of measurement standard deviation as a basis for the LOD (replicate
blank measurements, residuals from the calibration relationship, etc.). Few sources
discuss assumptions made with different choices of calibration regression on which the
LOD is based (normality of data, homoscedasticity of variance, false positive/negative
rates) (1-2), or the applicability of tolerance intervals to LOD calculations (3-5). This
research stands to clarify these ambiguities and to demonstrate the application of
tolerance intervals for calculating LOD in forensic dye analysis.
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Introduction
The ubiquitous nature of fibers provides an information-rich evidence source for crime
scene investigations; however, in cases of similarly dyed fibers, current fiber analysis
techniques do not provide adequate chemical information for unambiguous match
determinations to be made. We have targeted fiber sizes of 1 mm or less for our
extraction procedure to offset the issue of damaging evidence, and we use UPLC-DAD
(Ultra Performance Liquid Chromatography-Diode Array Detection) to achieve the
necessary sensitivity. In association with taking the smallest fiber size possible, we also
care to determine the limit of detection for each of the dyes.
Limit of detection (LOD, sometimes referred to as detection limit) does not carry a
consistent definition throughout the literature. Accreditation organizations and governing
bodies do not have specific definitions or defined ways to calculate LOD (6-14). Some
may put forth suggestions, but do not have detailed procedures. There is a lack of
consistent definitions, a lack of consistent notation, and calculations. In 1995, IUPAC
(International Union of Pure and Applied Chemistry), in an attempt to standardize
nomenclature, defined detection limit as “the measure of the inherent detection capability
of a chemical measurement process” (11). In 1997, IUPAC defined “the limit of
detection, expressed as the concentration, cL, or the quantity, qL, is derived from the
smallest measure, xL, that can be detected with reasonable certainty for a given analytical
procedure. The value of xL is given by the equation, 𝑥𝐿 = 𝑥̅𝑏𝑖 + k𝑠𝑏𝑖 , where 𝑥̅𝑏𝑖 is the
mean of the blank measures, sbi is the standard deviation of the blank measures, and k is a
numerical factor chosen according to the confidence level desired” (7). The factor k does
not have a defined value and values in the literature range from 2 to 3.3.6 IUPAC
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specifically gives an arbitrary value of k=3 (9). This IUPAC methodology is different
from that documented in ICH (International Conference on Harmonization) (14), the
Scientific Working Group for Forensic Toxicology (SWGTOX) (8), the Analytical
Methods Committee of the Royal Society of Chemistry (9), and countless other
guidelines and literature references. These inconsistencies lead to chemists unknowingly
making statistical errors and misguided laboratory comparisons. Most guidelines for
LOD gloss over two important issues: how can both false positive and false negative
errors be controlled, and how one handles calibration data that is heteroscedastic
(variability not the same at different analyte levels).
The research objective of this work is to demonstrate the forensic value of a statistically
sound approach for calculating the limit of detection with control of both false positive
and negative rates using statistical tolerance intervals and to evaluate the performance of
weighted least squares for a calibration model for heteroscedastic data.
Theory
LOD Meaning and Calculation
Limit of detection is the smallest measure, on the y-axis, that can be extrapolated to an xaxis concentration or quantity that can be reliably detected for an analytical method. A
limit of detection, traditionally a point estimate, has related false negative and false
positive error rates. A false negative is the error of not detecting analyte when it is, in
fact, present. A false positive is the error of detecting an analyte when it is, in fact, not
present. These concepts are shown in Table 6.1.
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Most existing LOD guidelines lack a detailed procedure for calculation of the limit of
detection, thus impeding inter-laboratory comparisons. Two laboratories may use the
same instrumental method, but the way in which LOD was calculated, if not identical,
skews the comparison. Even if the equation used in both cases is the same, interpretation
of the variables could vary. The largest variation in interpretation involves the source of
uncertainty employed in the LOD calculation: where should the standard deviation be
evaluated? As shown in Table 6.2, the variety of choices for calculation of the standard
deviation results in different LOD values. The measurement variability has been
estimated using the standard deviation of the blank and of the measurements, the lowest
non-zero calibrator, and the standard deviation of the residuals.
The number of standard deviations, k, above the mean of the blank measurements at
which the LOD is defined, determines the probability of false positive detection. No
single value for LOD is appropriate for all situations and, ultimately, the analyst should
think about the consequences of false positives and set LOD accordingly. LOD is often
defined as b + 3b, or as b + 3.3b, where b and b are the mean of the blank replicates
and a measure of the measurement uncertainty, respectively. The former is generally a
result of the rounding of the latter.2 If LOD is set at b + 3.3b, this point is also known
as the critical level when not being used as the LOD (3), the fractional risk, α, of
detecting analyte when, in fact, it is absent (false positive) is 0.0005. Thus, LOD is based
on setting the false positive risk to an acceptably low level by using an appropriately high
value for the k-multiplier. Historically, k values as low as 2 have been used (6). However,
the false negative error rate is 50% at any limit of detection so defined (2). This concept
is illustrated in Figure 1.
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The false negative rate decreases as the number of standard deviations, k, from the mean
that the LOD is determined to lie increases. The fractional false negative rate, β, falls to
0.0005, at 6.6b above the mean of the blank (Figure 6.2). At which level, analyte can be
detected consistently. The value at 6.6b gives sufficiently consistent detection, 99.95%
of the time, and is called the “minimum-consistently-detectable amount” (MCDA) (15).
If the analyte is present at the MCDA repeatedly, then it would only be incorrectly
assessed as absent (a false negative result) 0.05% of the time. However, there is no
confidence level associated with the MCDA.
Tolerance Intervals
If controlling both false positive and false negative error rates is of concern, with a
designated degree of confidence, then a tolerance interval is required. Statistical tolerance
intervals have not been often applied in practice, partly because of the paucity of
statistical tables for the asymmetric functions needed, and the complex calculations
required (1,3,16). However, sample calculations are available (5,10).
A tolerance interval is defined as an interval that contains at least a defined portion, p, of
the population with a defined degree of confidence, 100(1-α)%. As a result, there is
100(1-α)% confidence that the tolerance interval includes 100p% of the population (16).
The confidence level associated with the tolerance interval takes into account the fact that
the samples do not perfectly reflect the true population. Adjusting the confidence and
spread inherently adjusts the false negative and false positive rates, which can later be
determined. The higher the confidence and the spread, the lower the false positive and
false negative error rates. Adjusting the confidence and spread can be valuable when
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either the false positive or false negative result may have significant consequences (i.e.,
forensic cases that go to trial based on laboratory results). The tolerance interval can also
be adjusted to determine an upper or lower bound of a portion of the data. These upper
limits can help generate more accurate limits of detection. Statistical tolerance intervals
typically produce LODs higher than estimated using other approaches. Tolerance
intervals provide the best option for calculating limit of detection because it provides a
value that can be used for a “large and potentially unknown number of detection
decisions with a high, specified, degree of confidence” (3).
Assumptions
Most analysts use ordinary least squares (OLS) as a regression analysis technique. In
doing this, there are some basic assumptions that are made. Miller2 provides a description
of the three major assumptions: (1) errors made in measuring instrumental signals (ydirection error) are greater than all other errors, (2) y-direction error is normally
distributed, and (3) the data is homoscedastic. In general, if the OLS model does not pass
a lack-of-fit test, then a better investigation of the required assumptions may be
informative. If any of these assumptions cannot be upheld, then the OLS regression is not
the appropriate model.
The validity of the first assumption relies on the error of the standards versus error of the
instrumentation. Previously, the first assumption was generally taken as valid because the
instrumentation error outweighed the error of the standards. However, with modern day
instrumentation and standard reference materials, the two errors may be closer than most
would think. One can simply assess the relative standard deviation of the instrumental
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method compared to the relative standard deviation (RSD) of the reference material or
the in-house calibrators (propagation of error). If the instrumental RSD is not greater than
the calibrator RSD, then the assumption fails.
The residuals must be normally distributed. Normality can be easily detected by
examination of the plot of residuals. The data is normally distributed if the points lie
primarily at the predicted value with some residuals trailing off symmetrically. More
formal statistical tests exist that examine normality including an Anderson-Darling test or
a Shapiro-Wilks test.
The importance of the third assumption, homoscedasticity, lies in the fact that OLS
regression minimizes the sum of squares of residuals. If certain concentrations have
disproportionately high variance, then the regression coefficients estimation will be
unreasonably effected. Bartlett’s Test and Levene’s Test are useful for testing
homogeneity of the data. Another easy way of checking for constant variance is to simply
look at the residuals. A common way to counteract the heterogeneity of the variance is to
weight the dependent variable, as done with weighted least squares regression (WLS).
The weighting scheme generally results in homogenous variance which allows OLS to be
performed on the weighted regression.
Weighted Least Squares
The main assumption that generally does not hold with OLS, and is usually not tested for,
is homoscedasticity. When the data does not exhibit constant variance, OLS estimation is
still linear and unbiased, but it is not the minimum variance estimate which means that it
is inefficient (3). Weighted least squares (WLS) is a great technique when the data is
heteroscedastic and the analyst would prefer not to use a transformation model or one
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does not fit the data appropriately. Weighted least squares is an adaptation of OLS that
accounts for heterogeneity in variance. Weighted least squares regression is used by
applying a weight to each set of data points. Recommended weights vary, but the most
cited and most reflective of the data is a weight of the inverse of the variance at each set
of data points (4). By using the inverse of the variance as a weight, more weight is given
to the sets of data points with the least amount of variance and less weight to the sets of
data points with more uncertainty. In the present research, true variance was estimated
from the replicates, but variance modeling is a good alternative when replicate number is
small (4). Variance modeling can also be used to determine uncertainty between data
points. Another benefit of WLS is that the original data remain unchanged, i.e. there is no
need to refit response versus concentration. The model used in the present work is
explained by Zorn et al (3).
Experimental Section
Materials
Dyed fabric and textile dye standards were sampled from our collection of production
samples, which were donated by textile and dyestuff manufacturers from the southeastern
United States. The nine dyes selected for this study included three dyes from each of the
acid, basic, and disperse classes.
Fiber sample preparation
Individual fibers 5-mm in length were cut using a fiber guillotine; 1 mm and 0.5 mm
fibers were cut by hand using a table-mounted magnifying glass and scalpel. Each fiber
length was cut in triplicate. Cut fibers were then loaded into Waters Total Recovery®
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vials for extraction. These vials enable extractions to be performed with low solvent
volumes (< 50 μL), enabling concentration of dyes in the resulting extract.
Calibration design
Experimental designs for UPLC-DAD calibration were constructed for all nine dyes
based on 5 replicate experiments at 7 levels of dye concentration (0 ppb, 100 ppb, 500
ppb, 1000 ppb, 1500 ppb, 2000 ppb, and 2500 ppb). A blank sample was measured 15
times as a quality control sample interspersed through the runs. A lower concentration
design was also performed based on five replicate experiments using standard mixtures of
the 9 dyes at concentrations 10 ppb, 20 ppb, 30 ppb, 40 ppb, 50 ppb, and 18 blank
injections to better characterize low limits of detection. For each dye peak, QuanLynx™,
data management software included with MassLynx™ (Waters Corporation, Milford,
MA) was used to integrate peak areas above corrected baselines. For each dye standard at
1000 ppb concentration, the retention time window encompassing the baseline peak
width was determined; this window was then employed as the dye peak integration
window for all samples, including blanks.
Instrumentation
Dye standards and extracts were separated and detected using a Waters Acquity™ UPLC
H-Class equipped with a quaternary solvent pump system and a Waters PDA eλ detector.
The column was a 2.1 X 50 mm I.D. 1.7 μm particle size Waters Acquity™ BEH C18
column with a 2.1 X 5 mm I.D. 1.7 μm particle size Waters Acquity UPLC® BEH C18
VanGuard precolumn. The mobile phase gradient was based on mixtures of 50 mM
ammonium acetate in water and 0.15% formic acid in methanol. The column temperature
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was set at 40 °C. The diode array detector scanned the wavelength range from 325 nm to
675 nm at a rate of 40 Hz and 1.2 nm resolution. The sample injection volume was10 μL.
Results and Discussion
A fiber dye extraction method was calibrated at five different concentration points. After
looking at the residuals and calculating an F-test based on the OLS regression, it was
obvious that the data was heteroscedastic and did not fit the OLS model, shown in Figure
6.3. A WLS model was produced for each dye, yielding better residual standard
deviations in every case. Four examples of this are shown in Table 6.3. The residual
standard deviations of the WLS regression were all less than 0.1 suggesting a very good
correlation between the data and the model. According to Zeng, this behavior may be a
result of the chromatographic technique. “A growing body of evidence indicates that
chromatographic techniques are dominated by this type of heteroscedasticity over
sampling regions used in routine analytical work. Neglect of heteroscedasticity in
calibration, through use of unweighted or “ordinary” least squares (OLS) instead of
weighted least squares (WLS), can lead to significant loss of precision, especially in the
low signal limit which is often important in quantitating substances present at trace
levels” (17).
The limits of detection were calculated for the dyes as well; three examples are shown in
Table 6.4. It is made clear that the LOD values vary with the method used. LOD1-3 are
calculated via 3.3σb (this calculation was used for comparison purposes because it the
most common calculation used) but differ in the method of calculating σb, the standard
deviation of the blank. LOD1 estimates σb using the standard deviation of the integrated
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blank signals across the width of the peak. LOD2 estimates σb using the standard
deviation of the lowest non-zero calibrator (10 ppb). LOD3 estimates σb based on the
standard error of the y-intercept of the calibration model, i.e. the standard deviation of the
residuals. However, for LOD4, an upper one-sided tolerance interval was used.
A sample calculation of a simple non-simultaneous upper-limit tolerance interval based
on Acid Red 337 is shown below.
According to NIST (20), Upper One Sided Tolerance Interval:
𝑌𝑈 = 𝑌̅ + 𝑘1 𝑠
𝑘1 =

𝑧𝑝 + √𝑧𝑝2 − 𝑎𝑏
𝑎

𝑧𝛾2
𝑎 = 1−
2(𝑁 − 1)
𝑏=

𝑧𝑝2

𝑧𝛾2
−
𝑁

95% confidence (γ=0.99) & 99.95% population (p=0.95)
𝑧𝑝 = 3.291

𝑧𝑝2 = 10.831

𝑧𝛾 = 1.645
𝑎 = 1−

2.706
= 0.92041
2(18 − 1)

𝑏 = 10.831 −

𝑘1 =

𝑧𝛾2 = 2.706

2.706
= 10.68067
18

3.291 + √10.831 − (0.92041)(10.68067)
= 4.6623
0.92041
𝑌𝑈 = 𝑌̅ + 𝑘1 𝑠
𝑌𝑈 = 0.7126 + 4.6623(1.36) = 7.06 𝑝𝑝𝑏 (𝐿𝑂𝐷)
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The calculation requires a mean and standard deviation and a confidence and population
designation. The mean of this calculation must be the critical level, LC, (μb + 3.3σb)
because the LOD justified by the tolerance interval needs to be shifted to the right of the
critical level (where β is 0.5) to decrease the false negative rate, as is done with MCDA.
This “shift to the right” is shown by the variable k1 in the tolerance interval and
represents the number of standard deviations from the critical level that the LOD will be.
In total, the LOD will be 3.3 + k1 standard deviations from the blank. The standard
deviation used in the calculation is the standard deviation of the blank, which is assuming
homoscedasticity. In the future, variance modeling will be used to predict a more
accurate uncertainty at the LC and the LOD, as mentioned below. The confidence and
population coverage were set at 95% and 99.95%, respectively.
A population coverage of 99.95% (below the interval specified) allows for 0.0005 false
negative risk, shown in Figure 6.4. This is known because the standard deviation of the
two curves is equal. A false negative rate of 0.0005 makes the tolerance interval LOD
comparable to the MCDA. However, giving the tolerance interval a confidence level
makes it inherently more reliable than the MCDA. As a result, LOD generally lies further
from the blank than the MCDA. (i.e. 3.3 + k1 is greater than 3.3 + 3.3) With the specified
conditions, k1 is 4.6623, which means that the tolerance interval LOD is actually 1.3623
standard deviations further than the MCDA.
The point at which the LOD normal distribution and the distribution of the blank overlap
is called the critical level (μb + 3.3σb). The area of each curve that overlaps into the other
at the critical level represents either the false positive or false negative error, shown in
Figure 6.5. The rate of these errors decreases with the increase in number of standard
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deviations from the blank in which the LOD lies. Here this distance is controlled
primarily by the confidence and population spread chosen in the tolerance interval. In
other words, by increasing the confidence and the population percentages, the number of
standard deviations between the LOD and the blank will increase, thus decreasing the
false positive and false negative error rates. In general, the tolerance interval based LODs
were more conservative, which is to be expected.
Other means of calibration analysis include generalized least squares (GLS),
simultaneous tolerance intervals and modeling weights for least squares. GLS includes
uncertainties in the x-axis and the y-axis, unlike WLS (i.e. in GLS, there is no assumption
that errors in the y direction need to be larger than the errors in the x direction) (18).
However, there is the opposite assertion: there are errors in both the x and y direction;
therefore, GLS calibration requires uncertainty profiles for both the calibration solutions
(x direction) and their corresponding instrumental responses (y direction) (18). Once the
standard deviation in each direction is determined, the inverse variance weights can be
determined and applied.
The tolerance intervals described thus far have been non-simultaneous intervals.
However, simultaneous tolerance intervals can also be useful and can be broken down
into ordinary least squares intervals and weighted least squares intervals. Simultaneous
intervals span the entire calibration model and, in the case of tolerance intervals, give a
sense of uncertainty along the calibration. (i.e., for the future, the model will show an
interval where, for instance, 99.95% of the population will lie, at any given concentration
along the model, with 95% confidence). The simultaneous tolerance intervals require a
correlation between variance and concentration. In the OLS case, this is rather simple due

114

to the homoscedasticity. However, with WLS tolerance intervals, a proper model must be
fit to the relationship (described further in “modeling weights” below). Zorn and Gibbons
both discuss calculations for the weighted tolerance intervals (3-4). As a result of the
modeling of the variance, weighted tolerance interval width varies with concentration (4).
Because error generally increases with concentration, weighted tolerance intervals allow
for tighter tolerance intervals at lower concentrations which would result in lower and
more accurate limits of detection (3).
In the case of the weighted and generalized least squares regressions and the weighted
tolerance intervals, the weights are presumed to be known via analysis of the replicates or
by propagation of error. However, when the number of replicates is low or when the
propagation of error is too timely, the use of models to estimate the variance as a function
of concentration should be explored. Obviously, the best fit model should be used and
potential models include, but are not limited to, the Rocke and Lorenzo model,
exponential model, and a linear model (32). Modeling variance as a function of
concentration will also help to interpolate variances for future figures, including limit of
detection.
Conclusion
Limit of detection is an important figure of merit in forensic trace analysis. A consistent
limit of detection can be skewed through improper calculations. Firstly, it is imperative
that the proper regression model be chosen for the calibration data. Heteroscedasticity is
frequently overlooked and in its presence, weighted least squares regression is an
appropriate alternative to ordinary (unweighted) least squares. Tolerance intervals,
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specifically upper limit tolerance intervals, should be employed to determine the limit of
detection value. At this time, tolerance intervals are calculated with an assumption of
homoscedasticity, thus can only be used with OLS. Therefore, any extrapolation
(converting from the y-axis to the x-axis) during the tolerance interval calculation should
be done with the OLS regression model. Tolerance intervals give a conservative
estimation of limit of detection that can be implemented for an extended period of time.
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Table 6.1. Confusion Matrix of False Positives and False Negatives

Positive
TRUE
Negative

PREDICTED
Positive
Negative
True
False
Positive
Negative
False
True
Positive
Negative
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Table 6.2.
Effects on the limit of detection by estimating variability from
different sources.
Acid Red 337
σb
LOD Basis LOD
standard deviation of replicate
measurements of blanks, df = 14
standard deviation of the lowest non-zero
calibrator, df = 5
standard deviation of the residuals, df = 43
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3.07
3.3σb

1.89
0.86

Table 6.3.
Comparison of Calibration Parameters based on Unweighted versus Weighted Least
Squares Analysis
Least Squares Regression Parameters
Unweighted
Weighted
S,
S,
Dye
Intercept Slope
Intercept Slope
residuals
residuals
Acid Red 337
11.39
55.45
68.48
105.6
57.34
0.023
BasicYellow 28
93.52
56.32
62.68
110.7
55.02
0.046
Disperse Yellow 114
13.84
86.45
46.64
46.71
14.52
0.069
Basic Violet 16
93.65
109.7
122.5
95.97
93.94
0.037
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Table 6.4. Comparison of UPLC with UV/visible detection LODs for textile
dyes (in ppb) (𝑥𝐿𝑂𝐷 = 𝑥̅𝑏𝑙𝑎𝑛𝑘 + 3.3s) based on: (1) sb ; (2) s of the lowest nonzero concentration replicates; (3) s of the y-intercept of the calibration line; and
(4) a statistical tolerance interval.
DYE
LOD1
LOD2
LOD3
LOD4
Basic Violet 16
1.84
2.09
0.91
4.36
Basic Yellow 28
2.69
0.93
0.77
6.50
Acid Red 337
3.07
1.89
0.86
7.06

124

Figure 6.1. False positive and false negative risks for a sample containing analyte
equivalent to the amount at the limit of detection.
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Figure 6.2. For a sample that contains an amount of analyte that gives a signal equal to
the mean of the blank plus 6.6 standard deviations of the blank signal (twice that for
LOD), it can be said that analyte has been confidently detected (at or above the LOD),
and that the analyte is also consistently detected (at or above the MCDA).
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Figure 6.3. An example of heteroscedasticity in the Disperse Yellow 114 data. The
critical value of the F-Statistic with 41 degrees of freedom is 4.0785 at 95% confidence.
The calculated F-statistic for this data is 1268.7695. This exemplifies the lack of fit of the
ordinary least squares model.
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Figure 6.4. Comparison of the blank, critical level, and LOD distributions.
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12

14

Figure 6.5. Relationship between the blank, limit of detection, and the critical level.
Representation of the false positive and false negative error. LD is the limit of detection,
LC is the critical level, and the blank mean is shown to be zero (3).
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